

TITLE OF THE INVENTION
SALT FORMS WITH TYROSINE KINASE ACTIVITY

BACKGROUND OF THE INVENTION

5 The present invention relates to salt forms of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these salts, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, 10 atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.

10 Tyrosine kinases are a class of enzymes that catalyze the transfer of the terminal phosphate of adenosine triphosphate to tyrosine residues in protein substrates. Tyrosine kinases play critical roles in signal transduction for a number of 15 cell functions via substrate phosphorylation. Though the exact mechanisms of signal transduction is still unclear, tyrosine kinases have been shown to be important contributing factors in cell proliferation, carcinogenesis and cell differentiation.

20 Tyrosine kinases can be categorized as receptor type or non-receptor type. Receptor type tyrosine kinases have an extracellular, a transmembrane, and an intracellular portion, while non-receptor type tyrosine kinases are wholly intracellular.

25 The receptor-type tyrosine kinases are comprised of a large number of transmembrane receptors with diverse biological activity. In fact, about twenty different subfamilies of receptor-type tyrosine kinases have been identified. One tyrosine kinase subfamily, designated the HER subfamily, is comprised of EGFR, HER2, HER3, and HER4. Ligands of this subfamily of receptors include epithelial growth factor, TGF- α , amphiregulin, HB-EGF, betacellulin and heregulin. Another subfamily of these receptor-type tyrosine kinases is the insulin subfamily, which includes INS-R, IGF-IR, and IR-R. The PDGF subfamily includes the PDGF- α and β receptors, CSF1R, c-kit and FLK-II. Then there is the FLK family which is comprised 30 of the kinase insert domain receptor (KDR), fetal liver kinase-1 (FLK-1), fetal liver kinase-4 (FLK-4) and the fms-like tyrosine kinase-1 (flt-1). The PDGF and FLK families are usually considered together due to the similarities of the two groups. For a detailed discussion of the receptor-type tyrosine kinases, see Plowman et al., *DN&P* 7(6):334-339, 1994, which is hereby incorporated by reference.

The non-receptor type of tyrosine kinases is also comprised of numerous subfamilies, including Src, Frk, Btk, Csk, Abl, Zap70, Fes/Fps, Fak, Jak, Ack, and LIMK. Each of these subfamilies is further sub-divided into varying receptors. For example, the Src subfamily is one of the largest and includes Src, Yes, 5 Fyn, Lyn, Lck, Blk, Hck, Fgr, and Yrk. The Src subfamily of enzymes has been linked to oncogenesis. For a more detailed discussion of the non-receptor type of tyrosine kinases, see Bolen *Oncogene*, 8:2025-2031 (1993), which is hereby incorporated by reference.

Both receptor-type and non-receptor type tyrosine kinases are 10 implicated in cellular signaling pathways leading to numerous pathogenic conditions, including cancer, psoriasis and hyperimmune responses.

Several receptor-type tyrosine kinases, and the growth factors that bind thereto, have been suggested to play a role in angiogenesis, although some may promote angiogenesis indirectly (Mustonen and Alitalo, *J. Cell Biol.* 129:895-898, 15 1995). One such receptor-type tyrosine kinase is fetal liver kinase 1 or FLK-1. The human analog of FLK-1 is the kinase insert domain-containing receptor KDR, which is also known as vascular endothelial cell growth factor receptor 2 or VEGFR-2, since it binds VEGF with high affinity. Finally, the murine version of this receptor has also been called NYK (Oelrichs et al., *Oncogene* 8(1):11-15, 1993). VEGF and KDR are a 20 ligand-receptor pair that play an important role in the proliferation of vascular endothelial cells, and the formation and sprouting of blood vessels, termed vasculogenesis and angiogenesis, respectively.

Angiogenesis is characterized by excessive activity of vascular endothelial growth factor (VEGF). VEGF is actually comprised of a family of ligands 25 (Klagsburn and D'Amore, *Cytokine & Growth Factor Reviews* 7:259-270, 1996). VEGF binds the high affinity membrane-spanning tyrosine kinase receptor KDR and the related fms-like tyrosine kinase-1, also known as Flt-1 or vascular endothelial cell growth factor receptor 1 (VEGFR-1). Cell culture and gene knockout experiments indicate that each receptor contributes to different aspects of angiogenesis. KDR 30 mediates the mitogenic function of VEGF whereas Flt-1 appears to modulate non-mitogenic functions such as those associated with cellular adhesion. Inhibiting KDR thus modulates the level of mitogenic VEGF activity. In fact, tumor growth has been shown to be susceptible to the antiangiogenic effects of VEGF receptor antagonists. (Kim et al., *Nature* 362, pp. 841-844, 1993).

Solid tumors can therefore be treated by tyrosine kinase inhibitors since these tumors depend on angiogenesis for the formation of the blood vessels necessary to support their growth. These solid tumors include histiocytic lymphoma, cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung,
5 including lung adenocarcinoma and small cell lung cancer. Additional examples include cancers in which overexpression or activation of Raf-activating oncogenes (e.g., K-ras, erb-B) is observed. Such cancers include pancreatic and breast carcinoma. Accordingly, inhibitors of these tyrosine kinases are useful for the prevention and treatment of proliferative diseases dependent on these enzymes.

10 The angiogenic activity of VEGF is not limited to tumors. VEGF accounts for most of the angiogenic activity produced in or near the retina in diabetic retinopathy. This vascular growth in the retina leads to visual degeneration culminating in blindness. Ocular VEGF mRNA and protein are elevated by conditions such as retinal vein occlusion in primates and decreased pO₂ levels in mice
15 that lead to neovascularization. Intraocular injections of anti-VEGF monoclonal antibodies or VEGF receptor immunofusions inhibit ocular neovascularization in both primate and rodent models. Regardless of the cause of induction of VEGF in human diabetic retinopathy, inhibition of ocular VEGF is useful in treating the disease.

20 Expression of VEGF is also significantly increased in hypoxic regions of animal and human tumors adjacent to areas of necrosis. VEGF is also upregulated by the expression of the oncogenes ras, raf, src and mutant p53 (all of which are relevant to targeting cancer). Monoclonal anti-VEGF antibodies inhibit the growth of human tumors in nude mice. Although these same tumor cells continue to express VEGF in culture, the antibodies do not diminish their mitotic rate. Thus tumor-
25 derived VEGF does not function as an autocrine mitogenic factor. Therefore, VEGF contributes to tumor growth *in vivo* by promoting angiogenesis through its paracrine vascular endothelial cell chemotactic and mitogenic activities. These monoclonal antibodies also inhibit the growth of typically less well vascularized human colon cancers in athymic mice and decrease the number of tumors arising from inoculated
30 cells.


35 Viral expression of a VEGF-binding construct of Flk-1, Flt-1, the mouse KDR receptor homologue, truncated to eliminate the cytoplasmic tyrosine kinase domains but retaining a membrane anchor, virtually abolishes the growth of a transplantable glioblastoma in mice presumably by the dominant negative mechanism of heterodimer formation with membrane spanning endothelial cell VEGF receptors.

Embryonic stem cells, which normally grow as solid tumors in nude mice, do not produce detectable tumors if both VEGF alleles are knocked out. Taken together, these data indicate the role of VEGF in the growth of solid tumors. Inhibition of KDR or Flt-1 is implicated in pathological angiogenesis, and these receptors are 5 useful in the treatment of diseases in which angiogenesis is part of the overall pathology, e.g., inflammation, diabetic retinal vascularization, as well as various forms of cancer since tumor growth is known to be dependent on angiogenesis. (Weidner et al., N. Engl. J. Med., 324, pp. 1-8, 1991).

Although similar piperazinyl compounds have been previously 10 reported to be useful as tyrosine kinase inhibitors (see WO 01/17995, published March 15, 2001) a need still exists for forms of the compounds that can be readily administered to patients, especially active, soluble salts of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide that have thermal stability upon storage. Accordingly, the identification of salts of 4-[2-(5- 15 cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide, which specifically inhibit, regulate and/or modulate the signal transduction of tyrosine kinases, is desirable and is an object of this invention.

SUMMARY OF THE INVENTION

20 The present invention relates to salt forms of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. One embodiment of the present invention is illustrated by a salt of Formula I:



25

wherein

A^- is selected from hydrochloride, chloride ethanolate, tartrate, citrate or besylate salt.

DESCRIPTION OF THE FIGURES

Fig. 1: X-ray powder diffraction pattern of the hydrochloride salt (Form **C**) of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide.

5 Fig. 2: X-ray powder diffraction pattern of the hydrochloride salt (Form **D**) of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide.

10 Fig. 3: X-ray powder diffraction pattern of the hydrochloride salt (Form **E**) of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide.

Fig. 4: X-ray powder diffraction pattern of the hydrochloride salt (Form **F**) of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide.

15 Fig. 5: X-ray powder diffraction pattern of the hydrochloride ethanolate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide.

Fig. 6: X-ray powder diffraction pattern of the tartrate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide.

20 Fig. 7: X-ray powder diffraction pattern of the citrate salt (Form **G**) of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide.

25 Fig. 8: X-ray powder diffraction pattern of the citrate salt (Form **H**) of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide.

Fig. 9: X-ray powder diffraction pattern of the citrate salt (Form **I**) of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide.

30 Fig. 10: X-ray powder diffraction pattern of the besylate salt (Form **J**) of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide.

Fig. 11: X-ray powder diffraction pattern of the besylate salt (Form **K**) of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide.

DETAILED DESCRIPTION OF THE INVENTION

4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide (**Compound 4-4**) is an inhibitor of tyrosine kinase signal transduction and, in particular, inhibits the kinase KDR. The basic piperazine nitrogen of **Compound 4-4** will form salts upon treatment with various acids. Such salts include, but are not limited to, hydrochloride, chloride ethanolate, besylate, citrate and tartrate. Studies on the hydrochloride salt of **Compound 4-4** have revealed four different solid forms, Forms **C**, **D**, **E**, and **F**, as well as an additional hydrochloride ethanolate salt. Studies on the citrate salt of **Compound 4-4** have revealed three polymorphic forms, Forms **G**, **H** and **I**. Studies on the besylate salt of **Compound 4-4** have revealed two different polymorphic forms, Forms **J** and **K**.

It has been determined that the three of the polymorphous forms, Forms **C**, **D** and **E**, of the hydrochloride salt of **Compound 4-4** are monohydrates. Form **F** of the hydrochloride salt is an anhydrous form, which is obtained through the dehydration of Form **D**. Form **G** of the citrate salt of **Compound 4-4** is a monohydrate and Form **H** is a dihydrate. When Forms **G** and **H** are suspended and the solids are recovered, a distinct citrate salt (Form **I**) is obtained. Both Form **J** and Form **K** of the besylate salt are anhydrous.

An embodiment is illustrated by Form **C** of the hydrochloride salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in crystalline form characterized by an X-ray powder diffraction pattern having diffraction angles of: (with an experimental error of about $\pm 0.8^\circ$) 4.49, 9.08, 11.05, 17.76, 19.50, 21.36, 22.99, 27.69, 33.07 and 34.94.

A further embodiment is illustrated by Form **C** of the hydrochloride salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in crystalline form characterized by an X-ray powder diffraction pattern having multiple diffraction peaks between 2° and 35° 2-theta and a melting endotherm of 273°C at a rate of 5°C per minute.

Another embodiment is illustrated by Form **D** of the hydrochloride salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in crystalline form characterized by an X-ray powder diffraction pattern having diffraction angles of: (with an experimental error of about $\pm 0.8^\circ$) 9.14, 11.13, 15.65, 17.84, 19.60, 21.44, 23.92, 24.46, 25.17, 25.80, 25.98, 28.35 and 29.65.

And yet a further embodiment is illustrated by Form **D** of the hydrochloride salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-

piperazine-1-carboxylic acid methylamide in crystalline form characterized by an X-ray powder diffraction pattern having multiple diffraction peaks between 2° and 30° 2-theta and a melting endotherm at 264°C at a rate of 5°C per minute.

Another embodiment is illustrated by Form E of the hydrochloride salt
 5 of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in crystalline form characterized by an X-ray powder diffraction pattern having diffraction angles of: (with an experimental error of about ±0.8°) 4.13, 8.19, 9.97, 12.27, 15.21, 15.91, 16.56, 19.95, 20.23, 24.88 and 26.56.

And yet a further embodiment is illustrated by Form E of the
 10 hydrochloride salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in crystalline form characterized by an X-ray powder diffraction pattern having multiple diffraction peaks between 2 and 30° 2-theta and a melting endotherm of 246°C at a rate of 10°C per minute.

Another embodiment is illustrated by Form F of the hydrochloride salt
 15 of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in crystalline form characterized by an X-ray powder diffraction pattern having diffraction angles of: (with an experimental error of about ±0.8°) 10.17, 12.74, 15.01, 15.35, 16.09, 17.29, 17.89, 18.42, 18.88, 19.04, 20.00, 20.45, 21.49, 22.78, 24.44, 25.33, 26.04, 28.86, 30.31 and 31.00.

And yet a further embodiment is illustrated by Form F of the
 20 hydrochloride salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in crystalline form characterized by an X-ray powder diffraction pattern having multiple diffraction peaks between 2° and 35° 2-theta and a melting endotherm of 265°C at a rate of 5°C per minute.

Another embodiment is the hydrochloride ethanolate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in crystalline form characterized by an X-ray powder diffraction pattern having diffraction angles of: (with an experimental error of about ±0.8°) 6.09, 10.96, 12.03, 16.52, 16.79, 17.99, 18.31, 18.41, 19.87, 20.01, 21.42, 21.63, 24.82, 25.04,
 30 25.44, 25.81, 27.16, 29.92, 34.89, and 36.43.

And yet a further embodiment is illustrated by the hydrochloride ethanolate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in crystalline form characterized by an X-ray powder diffraction pattern having multiple diffraction peaks between 2° and 40° 2-theta and a melting endotherm of 268°C at a rate of 5°C per minute.
 35

Another embodiment is a tartrate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in crystalline form characterized by an X-ray powder diffraction pattern having diffraction angles of: (with an experimental error of about $\pm 0.8^\circ$) 10.22, 11.14, 13.44, 14.28, 16.76, 5 22.86, 24.98, 25.94, 28.72, and 29.86.

And yet a further embodiment is illustrated by the tartrate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in crystalline form characterized by an X-ray powder diffraction pattern having multiple diffraction peaks between 2° and 30° 2-theta and a melting endotherm 10 of 150°C at a rate of 10°C per minute.

Another embodiment is illustrated by Form **G** of the citrate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in crystalline form characterized by an X-ray powder diffraction pattern having multiple diffraction peaks between 2° and 30° 2-theta and a melting endotherm 15 of 153°C at a rate of 10°C per minute.

Another embodiment is illustrated by Form **H** of the citrate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in crystalline form characterized by an X-ray powder diffraction pattern having diffraction angles of: (with an experimental error of about $\pm 0.8^\circ$) 2.04, 4.16, 20 16.21, 16.31, 16.94, 17.72, 18.66, 19.61, 20.34, 20.97, 21.28, 21.46, 22.94, 23.98, 27.10, 27.85, 28.30.

And yet a further embodiment is illustrated by Form **H** of the citrate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in crystalline form characterized by an X-ray powder diffraction pattern having multiple diffraction peaks between 2° and 30° 2-theta and a melting endotherm 25 of 164°C at a rate of 5°C per minute.

Another embodiment is illustrated by Form **I** of the citrate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in crystalline form characterized by an X-ray powder diffraction pattern having diffraction angles of: (with an experimental error of about $\pm 0.8^\circ$) 4.51, 14.07, 30 15.09, 15.55, 15.82, 17.02, 17.70, 18.60, 20.70, 22.42, 23.71, 24.52, 25.40, 26.13, 27.91, 28.46, 28.58.

Another embodiment is illustrated by Form **J** of the besylate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in crystalline form characterized by an X-ray powder diffraction pattern 35


having diffraction angles of: (with an experimental error of about $\pm 0.8^\circ$) 9.54, 9.80, 12.90, 15.99, 18.54, 20.82, 21.16, 24.51.

. And yet a further embodiment is illustrated by Form J of the besylate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in crystalline form characterized by an X-ray powder diffraction pattern having multiple diffraction peaks between 2° and 25° 2-theta and a melting endotherm of 234°C at a rate of 5°C per minute.

Another embodiment is illustrated by Form K of the besylate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in crystalline form characterized by an X-ray powder diffraction pattern having diffraction angles of: (with an experimental error of about $\pm 0.8^\circ$) 8.66, 15.88, 16.27, 18.05, 18.43, 20.73, 22.94, 23.06, 23.64, 23.92, 24.34, 24.51.

And yet a further embodiment is illustrated by Form K of the besylate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in crystalline form characterized by an X-ray powder diffraction pattern having multiple diffraction peaks between 2° and 25° 2-theta and a melting endotherm of 232°C at a rate of 5°C per minute.

The salts of the present invention may have asymmetric centers, chiral axes, and chiral planes (as described in: E.L. Eliel and S.H. Wilen, *Stereochemistry of Carbon Compounds*, John Wiley & Sons, New York, 1994, pages 1119-1190), and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers and mixtures thereof, including optical isomers, being included in the present invention. In addition, the salts disclosed herein may exist as tautomers and both tautomeric forms are intended to be encompassed by the scope of the invention, even though only one tautomeric structure is depicted. For example, any claim to compound A below is understood to include tautomeric structure B, and vice versa, as well as mixtures thereof.



The instantly disclosed salts are inhibitors of tyrosine kinase and are therefore useful to treat or prevent tyrosine kinase-dependent diseases or conditions in mammals.

- “Tyrosine kinase-dependent diseases or conditions” refers to
- 5 pathologic conditions that depend on the activity of one or more tyrosine kinases. Tyrosine kinases either directly or indirectly participate in the signal transduction pathways of a variety of cellular activities including proliferation, adhesion and migration, and differentiation. Diseases associated with tyrosine kinase activities include the proliferation of tumor cells, the pathologic neovascularization that
- 10 supports solid tumor growth, ocular neovascularization (diabetic retinopathy, age-related macular degeneration, retinal ischemia, macular edema and the like) and inflammation (psoriasis, rheumatoid arthritis, and the like). In treating such conditions with the instantly claimed salts, the required therapeutic amount will vary according to the specific disease and is readily ascertainable by those skilled in the art.
- 15 Although both treatment and prevention are contemplated by the scope of the invention, the treatment of these conditions is the preferred use.

Also included within the scope of the claims is a composition which is comprised of a salt of the present invention and a pharmaceutically acceptable carrier.

- The present invention also encompasses a method of treating or
- 20 preventing cancer in a mammal in need of such treatment which is comprised of administering to said mammal a therapeutically effective amount of a presently disclosed salt. The term “treating cancer” or “treatment of cancer” refers to administration to a mammal afflicted with a cancerous condition and refers to an effect that alleviates the cancerous condition by killing the cancerous cells, but also to
- 25 an effect that results in the inhibition of growth and/or metastasis of the cancer.

- Preferred cancers for treatment are selected from cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung. Another set of preferred forms of cancer are histiocytic lymphoma, lung adenocarcinoma, small cell lung cancers, pancreatic cancer; glioblastomas and breast carcinoma. The utility of
- 30 angiogenesis inhibitors in the treatment of cancer is known in the literature, see J. Rak et al. *Cancer Research*, 55:4575-4580, 1995, for example. The role of angiogenesis in cancer has been shown in numerous types of cancer and tissues: breast carcinoma (G. Gasparini and A.L. Harris, *J. Clin. Oncol.*, 1995, 13:765-782; M. Toi et al., *Japan. J. Cancer Res.*, 1994, 85:1045-1049); bladder carcinomas (A.J. Dickinson

et al., *Br. J. Urol.*, 1994, 74:762-766); colon carcinomas (L.M. Ellis et al., *Surgery*, 1996, 120(5):871-878); and oral cavity tumors (J.K. Williams et al., *Am. J. Surg.*, 1994, 168:373-380).

Also included is a method of treating or preventing a disease in which
5 angiogenesis is implicated, which is comprised of administering to a mammal in need
of such treatment a therapeutically effective amount of a salt of the instant invention.
Such a disease in which angiogenesis is implicated is ocular diseases such as retinal
vascularization, diabetic retinopathy, age-related macular degeneration, retinal
ischemia, macular edema and the like.

10 Tumors which have undergone neovascularization show an increased
potential for metastasis. VEGF released from cancer cells enhances metastasis
possibly by increasing extravasation at points of adhesion to vascular endothelium.
(A. Amirkhosravi et al., *Platelets*, 10:285-292 (1999).) In fact, angiogenesis is
essential for tumor growth and metastasis. (S.P. Gunningham, et al., *Can. Research*,
15 61: 3206-3211 (2001)). The angiogenesis inhibitors disclosed in the present
application are therefore also useful to prevent or decrease tumor cell metastasis.
Such a use is also contemplated to be within the scope of the present invention.

Further included within the scope of the invention is a method of
treating or preventing a disease in which angiogenesis is implicated, which is
20 comprised of administering to a mammal in need of such treatment a therapeutically
effective amount of a salt of the instant invention. Ocular neovascular diseases are an
example of conditions where much of the resulting tissue damage can be attributed to
aberrant infiltration of blood vessels in the eye. (see WO 00/30651, published 2 June
2000.) The undesirable infiltration can be triggered by ischemic retinopathy, such as
25 that resulting from diabetic retinopathy, retinopathy of prematurity, retinal vein
occlusions, etc., or by degenerative diseases, such as the choroidal neovascularization
observed in age-related macular degeneration. Inhibiting the growth of blood vessels
by administration of a salt of the instant invention would therefore prevent the
infiltration of blood vessels and prevent or treat diseases where angiogenesis is
30 implicated, such as ocular diseases like retinal vascularization, diabetic retinopathy,
age-related macular degeneration, retinal ischemia, macular edema and the like.

A method of treating or preventing preeclampsia is also within the
scope of the present invention, which comprises administering a therapeutically
effective amount of a salt of the instant invention. Studies have shown that the action
35 of VEGF on the Flt-1 receptor is pivotal in the pathogenesis of preeclampsia.

(*Laboratory Investigation* 79:1101-1111 (September 1999)). Vessels of pregnant women incubated with VEGF exhibit a reduction in endothelium-dependent relaxation similar to that induced by plasma from women with preeclampsia. In the presence of an anti-Flt-1 receptor antibody, however, neither VEGF nor plasma from women with preeclampsia reduced the endothelium-dependent relaxation. Therefore the claimed salt of the instant invention serve to treat preeclampsia via their action on the tyrosine kinase domain of the Flt-1 receptor.

5 Also within the scope of the invention is a method of reducing or preventing tissue damage following a cerebral ischemic event which comprises 10 administering a therapeutically effective amount of a salt of the instant invention. The claimed salt can also be used to reduce or prevent tissue damage which occurs after cerebral ischemic events, such as stroke, by reducing cerebral edema, tissue damage, and reperfusion injury following ischemia. (*Drug News Perspect* 11:265-270 (1998); *J. Clin. Invest.* 104:1613-1620 (1999); *Nature Med* 7:222-227 (2001)).

15 Also included within the scope of the present invention is a method of treating or preventing inflammatory diseases which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a salt of the instant invention. Examples of such inflammatory diseases are rheumatoid arthritis, psoriasis, contact dermatitis, delayed hypersensitivity reactions, and the like. (A. 20 *Giatromanolaki et al., J. Pathol.* 2001; 194:101-108.)

25 Also included is a method of treating or preventing a tyrosine kinase-dependent disease or condition in a mammal which comprises administering to a mammalian patient in need of such treatment a therapeutically effective amount of a salt of the instant invention. The therapeutic amount varies according to the specific disease and is discernable to the skilled artisan without undue experimentation.

A method of treating or preventing retinal vascularization which is comprised of administering to a mammal in need of such treatment a therapeutically effective amount of a salt of the instant invention is also encompassed by the present invention. Methods of treating or preventing ocular diseases, such as diabetic 30 retinopathy, age-related macular degeneration, retinal ischemia and macular edema are also part of the invention. Also included within the scope of the present invention is a method of treating or preventing inflammatory diseases, such as rheumatoid arthritis, psoriasis, contact dermatitis and delayed hypersensitivity reactions, as well as treatment or prevention of bone associated pathologies selected from osteosarcoma, 35 osteoarthritis, and rickets, also known as oncogenic osteomalacia. (Hasegawa et al.,

Skeletal Radiol., 28, pp.41-45, 1999; Gerber et al., *Nature Medicine*, Vol. 5, No. 6, pp.623-628, June 1999). And since VEGF directly promotes osteoclastic bone resorption through KDR/Flk-1 expressed in mature osteoclasts (FEBS Let. 473:161-164 (2000); *Endocrinology*, 141:1667 (2000)), the instant salts are also useful to treat 5 and prevent conditions related to bone resorption, such as osteoporosis and Paget's disease.

The invention also contemplates the use of the instantly claimed salts in combination with another compound selected from:

- 10 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 15 7) an HMG-CoA reductase inhibitor,
- 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor, and
- 10) another angiogenesis inhibitor.

Preferred angiogenesis inhibitors are selected from the group 20 consisting of a tyrosine kinase inhibitor, an inhibitor of epidermal-derived growth factor, an inhibitor of fibroblast-derived growth factor, an inhibitor of platelet derived growth factor, an MMP (matrix metalloprotease) inhibitor, an integrin blocker, interferon- α , interleukin-12, pentosan polysulfate, a cyclooxygenase inhibitor, carboxyamido-triazole, combretastatin A-4, squalamine, 6-O-chloroacetyl-carbonyl)-25 fumagillol, thalidomide, angiostatin, troponin-1, and an antibody to VEGF. Preferred estrogen receptor modulators are tamoxifen and raloxifene.

Also included in the scope of the claims is a method of treating cancer which comprises administering a therapeutically effective amount of a salt of the instant invention in combination with radiation therapy and/or in combination with a 30 compound selected from:

- 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 35 5) an antiproliferative agent,

- 5
- 6) a prenyl-protein transferase inhibitor,
 - 7) an HMG-CoA reductase inhibitor,
 - 8) an HIV protease inhibitor,
 - 9) a reverse transcriptase inhibitor, and
 - 10) another angiogenesis inhibitor.

And yet another embodiment of the invention is a method of treating cancer which comprises administering a therapeutically effective amount of a salt of the instant invention in combination with paclitaxel or trastuzumab.

- 10 Also within the scope of the invention is a method of reducing or preventing tissue damage following a cerebral ischemic event which comprises administering a therapeutically effective amount of a salt of the instant invention.

Some of the abbreviations that may be used in the description of the chemistry and in the Examples include:

15	ACN	Acetonitrile;
	Ac ₂ O	Acetic anhydride;
	AcOH	Acetic acid;
	AIBN	2,2'-Azobisisobutyronitrile;
	BINAP	2,2'-Bis(diphenylphosphino)-1,1' binaphthyl;
20	Bn	Benzyl;
	BOC/Boc	<i>tert</i> -Butoxycarbonyl;
	BSA	Bovine Serum Albumin;
	CAN	Ceric Ammonia Nitrate;
	CBz	Carbobenzyloxy;
25	CI	Chemical Ionization;
	DBA	dibenzanthracene;
	DBAD	Di- <i>tert</i> -butyl azodicarboxylate;
	DBU	1,8-Diazabicyclo[5.4.0]undec-7-ene;
	DCE	1,2-Dichloroethane;
30	DEAD	diethylazodicarboxylate;
	DEM	diethoxymethane;
	DIAD	diisopropylazodicarboxylate;
	DIEA	<i>N,N</i> -Diisopropylethylamine;
	DMAC	N,N-dimethylacetamide;
35	DMAP	4-Dimethylaminopyridine;

	DME	1,2-Dimethoxyethane;
	DMF	<i>N,N</i> -Dimethylformamide;
	DMPU	1,3-Dimethyl-3,4,5,6-tetrahydro-2-(1 <i>H</i>)-pyrimidinone;
	DMSO	Methyl sulfoxide;
5	DPAD	dipiperidineazodicarbonyl;
	DPPA	Diphenylphosphoryl azide;
	DTT	Dithiothreitol;
	EDC	1-(3-Dimethylaminopropyl)-3-ethyl-carbodiimide-hydrochloride;
	EDTA	Ethylenediaminetetraacetic acid;
10	ES	Electrospray;
	ESI	Electrospray ionization;
	Et ₂ O	Diethyl ether;
	Et ₃ N	Triethylamine;
	EtOAc	Ethyl acetate;
15	EtOH	Ethanol;
	FAB	Fast atom bombardment;
	HEPES	4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid;
	HOAc	Acetic acid;
	HMTA	Hexamethylenetetramine;
20	HOBT	1-Hydroxybenzotriazole hydrate;
	HOOBT	3-Hydroxy-1,2,2-benzotriazin-4(3 <i>H</i>)-one;
	HPLC	High-performance liquid chromatography;
	HRMS	High Resolution Mass Spectroscopy;
	KOtBu	Potassium <i>tert</i> -butoxide;
25	LAH	Lithium aluminum hydride;
	LCMS	Liquid Chromatography Mass Spectroscopy;
	MCPBA	<i>m</i> -Chloroperoxybenzoic acid;
	Me	Methyl;
	MEK	Methyl ethyl ketone;
30	MeOH	Methanol;
	MIBK	Methyl isobutyl ketone;
	Ms	Methanesulfonyl;
	MS	Mass Spectroscopy;
	MsCl	Methanesulfonyl chloride;
35	MsOH	methanesulfonic acid;

	MTBE	<i>tert</i> -butyl methyl ether;
	n-Bu	<i>n</i> -butyl;
	n-Bu ₃ P	Tri- <i>n</i> -butylphosphine;
	NaHMDS	Sodium bis(trimethylsilyl)amide;
5	NBS	<i>N</i> -Bromosuccinimide;
	NMP	N-Methyl pyrrolidinone;
	ODCB	Ortho Dichlorobenzene, or 1,2-dichlorobenzene;
	Pd(PPh ₃) ₄	Palladium tetrakis(triphenylphosphine);
	Pd ₂ (dba) 2	Tris(dibenzylideneacetone)dipalladium (0)
10	Ph	phenyl;
	PMSF	α -Toluenesulfonyl fluoride;
	Py or pyr	Pyridine;
	PYBOP (or PyBOP)	Benzotriazol-1-yloxytritypyrrolidinophosphonium hexafluorophosphate;
15	RPLC	Reverse Phase Liquid Chromatography;
	rt (or RT)	Room Temperature;
	<i>t</i> -Bu	<i>tert</i> -Butyl;
	TBAF	Tetrabutylammonium fluoride;
	TBSCl	<i>tert</i> -Butyldimethylsilyl chloride;
20	TFA	Trifluoroacetic acid;
	THF	Tetrahydrofuran;
	TIPS	Triisopropylsilyl;
	TMEDA	N,N,N',N'-Tetramethylethylenediamine;
	TMS	Tetramethylsilane;
25	Tr	Trityl; and
	TsOH	P-Toluenesulfonic acid.

These and other aspects of the invention will be apparent from the teachings contained herein:

30

UTILITY

The salts of the instant invention are useful as pharmaceutical agents for mammals, especially for humans, in the treatment of tyrosine kinase dependent diseases. Such diseases include the proliferation of tumor cells, the pathologic

35

neovascularization (or angiogenesis) that supports solid tumor growth, ocular neovascularization (diabetic retinopathy, age-related macular degeneration, retinal ischemia, macular edema and the like) and inflammation (psoriasis, rheumatoid arthritis, and the like). Based on pharmacokinetic studies in animals, the presently claimed salts have an unexpectedly superior oral activity profile compared to the corresponding free base and are therefore particularly suited for oral administration. They may, however, be administered via other routes as described herein.

The salts of the instant invention may be administered to patients for use in the treatment of cancer. The instant salts inhibit tumor angiogenesis, thereby affecting the growth of tumors (J. Rak et al. *Cancer Research*, 55:4575-4580, 1995). The anti-angiogenesis properties of the instant salts are also useful in the treatment of certain forms of blindness related to retinal vascularization.

The salts of the instant invention are also useful in the treatment of certain bone-related pathologies, such as osteosarcoma, osteoarthritis, and rickets, also known as oncogenic osteomalacia. (Hasegawa et al., *Skeletal Radiol.*, 28, pp.41-45, 1999; Gerber et al., *Nature Medicine*, Vol. 5, No. 6, pp.623-628, June 1999). And since VEGF directly promotes osteoclastic bone resorption through KDR/Flk-1 expressed in mature osteoclasts (FEBS Let. 473:161-164 (2000); *Endocrinology*, 141:1667 (2000)), the instant salts are also useful to treat and prevent conditions related to bone resorption, such as osteoporosis and Paget's disease.

The claimed salts can also be used to reduce or prevent tissue damage which occurs after cerebral ischemic events, such as stroke, by reducing cerebral edema, tissue damage, and reperfusion injury following ischemia. (*Drug News Perspect* 11:265-270 (1998); *J. Clin. Invest.* 104:1613-1620 (1999).)

The salts of the instant invention may also be co-administered with other well known therapeutic agents that are selected for their particular usefulness against the condition that is being treated. For example, in the case of bone-related disorders, combinations that would be useful include those with antiresorptive bisphosphonates, such as alendronate and risedronate; integrin blockers (defined further below), such as $\alpha_v\beta_3$ antagonists; conjugated estrogens used in hormone replacement therapy, such as PREMPRO®, PREMARIN® and ENDOMETRION®; selective estrogen receptor modulators (SERMs), such as raloxifene, droloxifene, CP-336,156 (Pfizer) and lasofoxifene; cathepsin K inhibitors; and ATP proton pump inhibitors.

The instant salts are also useful in combination with known anti-cancer agents. Such known anti-cancer agents include the following: estrogen receptor modulators, androgen receptor modulators, retinoid receptor modulators, cytotoxic agents, antiproliferative agents, prenyl-protein transferase inhibitors, HMG-CoA reductase inhibitors, HIV protease inhibitors, reverse transcriptase inhibitors, and other angiogenesis inhibitors.

“Estrogen receptor modulators” refers to compounds which interfere or inhibit the binding of estrogen to the receptor, regardless of mechanism. Examples of estrogen receptor modulators include, but are not limited to, tamoxifen, raloxifene, 10 idoxifene, LY353381, LY117081 , toremifene, fulvestrant, 4-[7-(2,2-dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl-2,2-dimethylpropanoate, 4,4’-dihydroxybenzophenone-2,4-dinitrophenylydrazone, and SH646.

“Androgen receptor modulators” refers to compounds which interfere or inhibit the binding of androgens to the receptor, regardless of mechanism. Examples of androgen receptor modulators include finasteride and other 5 α -reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozole, and abiraterone acetate.

“Retinoid receptor modulators” refers to compounds which interfere or inhibit the binding of retinoids to the receptor, regardless of mechanism. Examples of such retinoid receptor modulators include bexarotene, tretinooin, 13-cis-retinoic acid, 9-cis-retinoic acid, α -difluoromethylomithine, ILX23-7553, trans-N-(4'-hydroxyphenyl)retinamide, and N-4-carboxyphenyl retinamide.

“Cytotoxic agents” refer to compounds which cause cell death primarily by interfering directly with the cell’s functioning or inhibit or interfere with cell myosis, including alkylating agents, tumor necrosis factors, intercalators, microtubulin inhibitors, and topoisomerase inhibitors.

Examples of cytotoxic agents include, but are not limited to, tirapazimine, sertene, cachectin, ifosfamide, tasonermin, lonidamine, carboplatin, altretamine, prednimustine, dibromodulcitol, ranimustine, fotemustine, nedaplatin, 30 oxaliplatin, temozolomide, heptaplatin, estramustine, imrosulfan tosilate, trofosfamide, nimustine, dibrosipidium chloride, pumitepa, lobaplatin, satraplatin, profiromycin, cisplatin, irofulven, dexifosfamide, cis-aminedichloro(2-methyl-pyridine) platinum, benzylguanine, glufosfamide, GPX100, (trans, trans, trans)-bis-mu-(hexane-1,6-diamine)-mu-[diamine-platinum(II)]bis[diamine(chloro) platinum (II)]tetrachloride, diarizidinylspermine, arsenic trioxide, 1-(11-dodecylamino-10-

hydroxyundecyl)-3,7-dimethylxanthine, zorubicin, idarubicin, bisantrene, mitoxantrone, pirarubicin, pinafide, valrubicin, amrubicin, antineoplaston, 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin, annamycin, galarubicin, elinafide, MEN10755, and 4-demethoxy-3-deamino-3-aziridinyl-4-methylsulphonyl-daunorubicin.


Examples of microtubulin inhibitors include paclitaxel, vindesine sulfate, 3',4'-didehydro-4'-deoxy-8'-norvincaleukoblastine, docetaxol, rhizoxin, dolastatin, mivobulin isethionate, auristatin, cemadotin, RPR109881, BMS184476, vinflunine, cryptophycin, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl) enzene sulfonamide, anhydrovinblastine, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline-t-butylamide, TDX258, and BMS188797.

Some examples of topoisomerase inhibitors are topotecan, hycaptamine, irinotecan, rubitecan, 6-ethoxypropionyl-3',4'-O-exo-benzylidene-chartreusin, 9-methoxy-N,N-dimethyl-5-nitropyrazolo[3,4,5-kl]acridine-2-(6H) propanamine, 1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H, 12H-benzo[de]pyrano[3',4':b,7]indolizino[1,2b]quinoline-10,13(9H,15H)dione, lurttotecan, 7-[2-(N-isopropylamino)ethyl]-(20S)camptothecin, BNP1350, BNPII1100, BN80915, BN80942, etoposide phosphate, teniposide, sobuzoxane, 2'-dimethylamino-2'-deoxy-etoposide, GL331, N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide, asulacrine, (5a, 5aB, 8aa,9b)-9-[2-[N-[2-(dimethylamino)ethyl]-N-methylamino]ethyl]-5-[4-hydroxy-3,5-dimethoxyphenyl]-5,5a,6,8,8a,9-hexohydrofuro(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6-one, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]-phenanthridinium, 6,9-bis[(2-aminoethyl)amino]benzo[g]isoguinoline-5,10-dione, 5-(3-aminopropylamino)-7,10-dihydroxy-2-(2-hydroxyethylaminomethyl)-6H-pyrazolo[4,5,1-de]acridin-6-one, N-[1-[2(diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl]formamide, N-(2-(dimethylamino)ethyl)acridine-4-carboxamide, 6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one; and dimesna.

“Antiproliferative agents” includes antisense RNA and DNA oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231, and INX3001, and antimetabolites such as enocitabine, carmofur, tegafur, pentostatin, doxifluridine, trimetrexate, fludarabine, capecitabine, galocitabine, cytarabine ocfosfate, fosteabine sodium hydrate, raltitrexed, paltitrexid, emitefur, tiazofurin, decitabine, nolatrexed, pemtrexed, nelzarabine, 2'-deoxy-2'-methylidenecytidine, 2'-fluoromethylene-2'-

- deoxycytidine, N-[5-(2,3-dihydro-benzofuryl)sulfonyl]-N'-(3,4-dichlorophenyl) urea, N6-[4-deoxy-4-[N2-[2(E),4(E)-tetradecadienoyl]glycylamino]-L-glycero-B-L-manno-heptopyranosyl]adenine, aplidine, ecteinascidin, troxacitabine, 4-[2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4-b][1,4]thiazin-6-yl-(S)-ethyl]-2,5-thienoyl-L-glutamic acid, aminopterin, 5-flurouracil, alanosine, 11-acetyl-8-(carbamoyloxymethyl)-4-formyl-6-methoxy-14-oxa-1,11-diazatetracyclo(7.4.1.0.0)-tetradeca-2,4,6-trien-9-yl acetic acid ester, swainsonine, lometrexol, dexamoxane, methioninase, 2'-cyano-2'-deoxy-N4-palmitoyl-1-B-D-arabino furanosyl cytosine, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone. “Antiproliferative agents” also includes monoclonal antibodies to growth factors, other than those listed under “angiogenesis inhibitors”, such as trastuzumab, and tumor suppressor genes, such as p53, which can be delivered via recombinant virus-mediated gene transfer (see U.S. Patent No. 6,069,134, for example).
- “HMG-CoA reductase inhibitors” refers to inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase. Compounds which have inhibitory activity for HMG-CoA reductase can be readily identified by using assays well-known in the art. For example, see the assays described or cited in U.S. Patent 4,231,938 at col. 6, and WO 84/02131 at pp. 30-33. The terms “HMG-CoA reductase inhibitor” and “inhibitor of HMG-CoA reductase” have the same meaning when used herein.
- Examples of HMG-CoA reductase inhibitors that may be used include but are not limited to lovastatin (MEVACOR®; see U.S. Patent Nos. 4,231,938, 4,294,926 and 4,319,039), simvastatin (ZOCOR®; see U.S. Patent Nos. 4,444,784, 4,820,850 and 4,916,239), pravastatin (PRAVACHOL®; see U.S. Patent Nos. 4,346,227, 4,537,859, 4,410,629, 5,030,447 and 5,180,589), fluvastatin (LESCOL®; see U.S. Patent Nos. 5,354,772, 4,911,165, 4,929,437, 5,189,164, 5,118,853, 5,290,946 and 5,356,896), atorvastatin (LIPITOR®; see U.S. Patent Nos. 5,273,995, 4,681,893, 5,489,691 and 5,342,952) and cerivastatin (also known as rivastatin and BAYCHOL®; see U.S. Patent No. 5,177,080). The structural formulas of these and additional HMG-CoA reductase inhibitors that may be used in the instant methods are described at page 87 of M. Yalpani, “Cholesterol Lowering Drugs”, *Chemistry & Industry*, pp. 85-89 (5 February 1996) and U.S. Patent Nos. 4,782,084 and 4,885,314. The term HMG-CoA reductase inhibitor as used herein includes all pharmaceutically acceptable lactone and open-acid forms (i.e., where the lactone ring is opened to form the free acid) as well as salt and ester forms of compounds which have HMG-CoA reductase inhibitory activity, and therefore the use of such salts, esters, open-acid and

lactone forms is included within the scope of this invention. An illustration of the lactone portion and its corresponding open-acid form is shown below as structures I and II.



- 5 In HMG-CoA reductase inhibitors where an open-acid form can exist, salt and ester forms may preferably be formed from the open-acid, and all such forms are included within the meaning of the term "HMG-CoA reductase inhibitor" as used herein. Preferably, the HMG-CoA reductase inhibitor is selected from lovastatin and simvastatin, and most preferably simvastatin. Herein, the term "pharmaceutically acceptable salts" with respect to the HMG-CoA reductase inhibitor shall mean non-toxic salts of the compounds employed in this invention which are generally prepared by reacting the free acid with a suitable organic or inorganic base, particularly those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc and tetramethylammonium, as well as those salts formed from 10 amines such as ammonia, ethylenediamine, N-methylglucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chlorprocaine, diethanolamine, procaine, N-benzylphenethylamine, 1-p-chlorobenzyl-2-pyrrolidine-1'-yl-methylbenzimidazole, diethylamine, piperazine, and tris(hydroxymethyl)aminomethane. Further examples of salt forms of HMG-CoA reductase inhibitors 15 may include, but are not limited to, acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, 20 lactobionate, laurate, malate, maleate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, pamaote, palmitate, panthenate, phosphate/ 25 napsylate, nitrate, oleate, oxalate, pamaote, palmitate, panthenate, phosphate/

diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, tannate, tartrate, teoclolate, tosylate, triethiodide, and valerate.

Ester derivatives of the described HMG-CoA reductase inhibitor compounds may act as prodrugs which, when absorbed into the bloodstream of a warm-blooded animal, may cleave in such a manner as to release the drug form and permit the drug to afford improved therapeutic efficacy.

"Prenyl-protein transferase inhibitor" refers to a compound which inhibits any one or any combination of the prenyl-protein transferase enzymes, including farnesyl-protein transferase (FPTase), geranylgeranyl-protein transferase type I (GGPTase-I), and geranylgeranyl-protein transferase type-II (GGPTase-II, also called Rab GGPTase). Examples of prenyl-protein transferase inhibiting compounds include (+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1*H*)-quinolinone, (-)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1*H*)-quinolinone, (+)-16-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1*H*)-quinolinone, 5(S)-n-butyl-1-(2,3-dimethylphenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinone, (S)-1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-5-[2-(ethanesulfonyl)methyl]-2-piperazinone, 5(S)-n-Butyl-1-(2-methylphenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinone, 1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)-2-methyl-5-imidazolylmethyl]-2-piperazinone, 1-(2,2-diphenylethyl)-3-[N-(1-(4-cyanobenzyl)-1H-imidazol-5-ylethyl)carbamoyl]piperidine, 4-{5-[4-Hydroxymethyl-4-(4-chloropyridin-2-ylmethyl)-piperidine-1-ylmethyl]-2-methylimidazol-1-ylmethyl}benzonitrile, 4-{5-[4-hydroxymethyl-4-(3-chlorobenzyl)-piperidine-1-ylmethyl]-2-methylimidazol-1-ylmethyl}benzonitrile, 4-{3-[4-(2-oxo-2*H*-pyridin-1-yl)benzyl]-3*H*-imidazol-4-ylmethyl}benzonitrile, 4-{3-[4-(5-chloro-2-oxo-2*H*-[1,2']bipyridin-5'-ylmethyl]-3*H*-imidazol-4-ylmethyl}benzonitrile, 4-{3-[4-(2-Oxo-2*H*-[1,2']bipyridin-5'-ylmethyl]-3*H*-imidazol-4-ylmethyl}benzonitrile, 4-[3-(2-Oxo-1-phenyl-1,2-dihydropyridin-4-ylmethyl)-3*H*-imidazol-4-ylmethyl}benzonitrile, 18,19-dihydro-19-oxo-5*H*,17*H*-6,10:12,16-dimetheno-1*H*-imidazo[4,3-*c*][1,11,4]dioxaazacyclo-nonadecine-9-carbonitrile, (\pm)-19,20-Dihydro-19-oxo-5*H*-18,21-ethano-12,14-etheno-6,10-metheno-22*H*-benzo[*d*]imidazo[4,3-*k*][1,6,9,12]oxatriaza-cyclooctadecine-9-carbonitrile, 19,20-dihydro-19-oxo-5*H*,17*H*-18,21-ethano-6,10:12,16-dimetheno-22*H*-imidazo[3,4-*h*][1,8,11,14]oxatriazacycloicosine-9-carbonitrile, and (\pm)-19,20-

Dihydro-3-methyl-19-oxo-5*H*-18,21-ethano-12,14-etheno-6,10-metheno-22*H*-benzo [*d*]imidazo[4,3-*k*][1,6,9,12]oxa-triazacyclooctadecine-9-carbonitrile.

- Other examples of prenyl-protein transferase inhibitors can be found in the following publications and patents: WO 96/30343, WO 97/18813, WO 97/21701, 5 WO 97/23478, WO 97/38665, WO 98/28980, WO 98/29119, WO 95/32987, U.S. Patent No. 5,420,245, U.S. Patent No. 5,523,430, U.S. Patent No. 5,532,359, U.S. Patent No. 5,510,510, U.S. Patent No. 5,589,485, U.S. Patent No. 5,602,098, European Patent Publ. 0 618 221, European Patent Publ. 0 675 112, European Patent Publ. 0 604 181, European Patent Publ. 0 696 593, WO 94/19357, WO 95/08542, 10 WO 95/11917, WO 95/12612, WO 95/12572, WO 95/10514, U.S. Patent No. 5,661,152, WO 95/10515, WO 95/10516, WO 95/24612, WO 95/34535, WO 95/25086, WO 96/05529, WO 96/06138, WO 96/06193, WO 96/16443, WO 96/21701, WO 96/21456, WO 96/22278, WO 96/24611, WO 96/24612, WO 96/05168, WO 96/05169, WO 96/00736, U.S. Patent No. 5,571,792, 15 WO 96/17861, WO 96/33159, WO 96/34850, WO 96/34851, WO 96/30017, WO 96/30018, WO 96/30362, WO 96/30363, WO 96/31111, WO 96/31477, WO 96/31478, WO 96/31501, WO 97/00252, WO 97/03047, WO 97/03050, WO 97/04785, WO 97/02920, WO 97/17070, WO 97/23478, WO 97/26246, WO 97/30053, WO 97/44350, WO 98/02436, and U.S. Patent No. 5,532,359. 20 For an example of the role of a prenyl-protein transferase inhibitor on angiogenesis see European J. of Cancer, Vol. 35, No. 9, pp.1394-1401 (1999).

Examples of HIV protease inhibitors include amprenavir, abacavir, CGP-73547, CGP-61755, DMP-450, indinavir, nelfinavir, tipranavir, ritonavir, saquinavir, ABT-378, AG 1776, and BMS-232,632. Examples of reverse transcriptase inhibitors include delavirdine, efavirenz, GS-840, HB Y097, lamivudine, nevirapine, AZT, 3TC, ddC, and dDI.

“Angiogenesis inhibitors” refers to compounds that inhibit the formation of new blood vessels, regardless of mechanism. Examples of angiogenesis inhibitors include, but are not limited to, tyrosine kinase inhibitors, such as inhibitors of the tyrosine kinase receptors Flt-1 (VEGFR1) and Flk-1/KDR (VEGFR20), inhibitors of epidermal-derived, fibroblast-derived, or platelet derived growth factors, MMP (matrix metalloprotease) inhibitors, integrin blockers, interferon- α , interleukin-12, pentosan polysulfate, cyclooxygenase inhibitors, including nonsteroidal anti-inflammatories (NSAIDs) like aspirin and ibuprofen as well as selective cyclo-

oxygenase-2 inhibitors like celecoxib and rofecoxib (PNAS, Vol. 89, p. 7384 (1992); JNCI, Vol. 69, p. 475 (1982); Arch. Ophthalmol., Vol. 108, p. 573 (1990); Anat. Rec., Vol. 238, p. 68 (1994); FEBS Letters, Vol. 372, p. 83 (1995); Clin. Orthop. Vol. 313, p. 76 (1995); J. Mol. Endocrinol., Vol. 16, p. 107 (1996); Jpn. J. Pharmacol., Vol. 75, p. 105 (1997); Cancer Res., Vol. 57, p. 1625 (1997); Cell, Vol. 93, p. 705 (1998); Intl. J. Mol. Med., Vol. 2, p. 715 (1998); J. Biol. Chem., Vol. 274, p. 9116 (1999)), carboxyamidotriazole, combretastatin A-4, squalamine, 6-O-chloroacetyl-carbonyl-fumagillo, thalidomide, angiostatin, troponin-1, angiotensin II antagonists (see Fernandez et al., J. Lab. Clin. Med. 105:141-145 (1985)), and antibodies to VEGF (see, Nature Biotechnology, Vol. 17, pp. 963-968 (October 1999); Kim et al., Nature, 362, 841-844 (1993) WO 00/44777; and WO 00/61186).

Other therapeutic agents that modulate or inhibit angiogenesis and may also be used in combination with the salts of the instant invention include agents that modulate or inhibit the coagulation and fibrinolysis systems (see review in *Clin. Chem. La. Med.* 38:679-692 (2000)). Examples of such agents that modulate or inhibit the coagulation and fibrinolysis pathways include, but are not limited to, heparin (see *Thromb. Haemost.* 80:10-23 (1998)), low molecular weight heparins and carboxypeptidase U inhibitors (also known as inhibitors of active thrombin activatable fibrinolysis inhibitor [TAFIa]) (see *Thrombosis Res.* 101:329-354 (2001)). TAFIa inhibitors have been described in U.S. Ser. Nos. 60/310,927 (filed August 8, 2001) and 60/349,925 (filed January 18, 2002).

As described above, the combinations with NSAID's are directed to the use of NSAID's which are potent COX-2 inhibiting agents. For purposes of this specification an NSAID is potent if it possess an IC₅₀ for the inhibition of COX-2 of 1μM or less as measured by the cell or microsomal assay disclosed herein.


The invention also encompasses combinations with NSAID's which are selective COX-2 inhibitors. For purposes of this specification NSAID's which are selective inhibitors of COX-2 are defined as those which possess a specificity for inhibiting COX-2 over COX-1 of at least 100 fold as measured by the ratio of IC₅₀ for COX-2 over IC₅₀ for COX-1 evaluated by the cell or microsomal assay disclosed hereinunder. Such compounds include, but are not limited to those disclosed in U.S. 5,474,995, issued December 12, 1995, U.S. 5,861,419, issued January 19, 1999, U.S. 6,001,843, issued December 14, 1999, U.S. 6,020,343, issued February 1, 2000, U.S. 5,409,944, issued April 25, 1995, U.S. 5,436,265, issued July 25, 1995, U.S. 5,536,752, issued July 16, 1996, U.S. 5,550,142, issued August 27, 1996,

- U.S. 5,604,260, issued February 18, 1997, U.S. 5,698,584, issued December 16, 1997,
 U.S. 5,710,140, issued January 20, 1998, WO 94/15932, published July 21, 1994,
 U.S. 5,344,991, issued June 6, 1994, U.S. 5,134,142, issued July 28, 1992,
 U.S. 5,380,738, issued January 10, 1995, U.S. 5,393,790, issued February 20, 1995,
 5 U.S. 5,466,823, issued November 14, 1995 (Celebrex), U.S. 5,633,272, issued May
 27, 1997 (Valdecoxib), and U.S. 5,932,598, issued August 3, 1999 (Parecoxib), all of
 which are hereby incorporated by reference.


Inhibitors of COX-2 that are particularly useful in the instant method
 of treatment are:

10

3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone; and





5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine;




15 or a pharmaceutically acceptable salt thereof.

General and specific synthetic procedures for the preparation of the
 COX-2 inhibitor compounds described above are found in U.S. Patent No. 5,474,995,
 issued December 12, 1995, U.S. Patent No. 5,861,419, issued January 19, 1999, and
 U.S. Patent No. 6,001,843, issued December 14, 1999, all of which are herein
 20 incorporated by reference.

Compounds that have been described as specific inhibitors of COX-2 and are therefore useful in the present invention include, but are not limited to, the following:



5



or a pharmaceutically acceptable salt thereof.

Compounds, which are described as specific inhibitors of COX-2 and are therefore useful in the present invention, and methods of synthesis thereof, can be found in the following patents, pending applications and publications, which are herein incorporated by reference: WO 94/15932, published July 21, 1994, U.S. Patent No. 5,344,991, issued June 6, 1994, U.S. Patent No. 5,134,142, issued July 28, 1992,

U.S. Patent No. 5,380,738, issued January 10, 1995, U.S. Patent No. 5,393,790, issued February 20, 1995, U.S. Patent No. 5,466,823, issued November 14, 1995 (Celebrex), U.S. Patent No. 5,633,272, issued May 27, 1997 (Valdecoxib), and U.S. Patent No. 5,932,598, issued August 3, 1999 (Parecoxib).

5 Compounds which are specific inhibitors of COX-2 and are therefore useful in the present invention, and methods of synthesis thereof, can be found in the following patents, pending applications and publications, which are herein incorporated by reference: U.S. Patent No. 5,474,995 issued December 12, 1995, U.S. Patent No. 5,861,419 issued January 19, 1999, U.S. Patent No. 6,001,843 issued
 10 December 14, 1999, U.S. Patent No. 6,020,343 issued February 1, 2000, U.S. Patent No. 5,409,944 issued April 25, 1995, U.S. Patent No. 5,436,265 issued July 25, 1995, U.S. Patent No. 5,536,752 issued July 16, 1996, U.S. Patent No. 5,550,142 issued August 27, 1996, U.S. Patent No. 5,604,260 issued February 18, 1997, U.S. Patent No. 5,698,584 issued December 16, 1997, and U.S. Patent No. 5,710,140 issued
 15 January 20, 1998.

Other examples of angiogenesis inhibitors include, but are not limited to, endostatin, ukrain, ranpirinase, IM862, 5-methoxy-4-[2-methyl-3-(3-methyl-2-but enyl)oxiranyl]-1-oxaspiro[2,5]oct-6-yl(chloroacetyl)carbamate, acetyldinanaline, 5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]-1H-1,2,3-triazole-4-carboxamide, CM101, squalamine, combretastatin, RPI4610, NX31838, sulfated mannopentaose phosphate, 7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolocarbonyl-imino[N-methyl-4,2-pyrrole]-carbonylimino]-bis-(1,3-naphthalene disulfonate), and 3-[(2,4-dimethylpyrrol-5-yl)methylene]-2-indolinone (SU5416).

As used above, "integrin blockers" refers to compounds which
 25 selectively antagonize, inhibit or counteract binding of a physiological ligand to the $\alpha\beta 3$ integrin, to compounds which selectively antagonize, inhibit or counter-act binding of a physiological ligand to the $\alpha\beta 5$ integrin, to compounds which antagonize, inhibit or counteract binding of a physiological ligand to both the $\alpha\beta 3$ integrin and the $\alpha\beta 5$ integrin, and to compounds which antagonize, inhibit or
 30 counteract the activity of the particular integrin(s) expressed on capillary endothelial cells. The term also refers to antagonists of the $\alpha\beta 6$, $\alpha\beta 8$, $\alpha 1\beta 1$, $\alpha 2\beta 1$, $\alpha 5\beta 1$, $\alpha 6\beta 1$ and $\alpha 6\beta 4$ integrins. The term also refers to antagonists of any combination of $\alpha\beta 3$, $\alpha\beta 5$, $\alpha\beta 6$, $\alpha\beta 8$, $\alpha 1\beta 1$, $\alpha 2\beta 1$, $\alpha 5\beta 1$, $\alpha 6\beta 1$ and $\alpha 6\beta 4$ integrins.

Some specific examples of tyrosine kinase inhibitors include N-
 35 (trifluoromethylphenyl)-5-methylisoxazol-4-carboxamide, 3-[(2,4-dimethylpyrrol-

- 5-yl)methylidenyl)indolin-2-one, 17-(allylamino)-17-demethoxygeldanamycin, 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxyl]quinazoline, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, BIBX1382, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-hydroxy-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, SH268, genistein, STI571, CEP2563, 4-(3-chlorophenylamino)-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidinemethane sulfonate, 4-(3-bromo-4-hydroxyphenyl)amino-6,7-dimethoxyquinazoline, 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline, SU6668, STI571A, N-4-chlorophenyl-4-(4-pyridylmethyl)-1-phthalazinamine, and EMD121974.

The instantly claimed salts are also useful, alone or in combination with platelet fibrinogen receptor (GP IIb/IIIa) antagonists, such as tirofiban, to inhibit metastasis of cancerous cells. Tumor cells can activate platelets largely via thrombin generation. This activation is associated with the release of VEGF. The release of VEGF enhances metastasis by increasing extravasation at points of adhesion to vascular endothelium (Amirkhosravi, *Platelets* 10, 285-292, 1999). Therefore, the present salts can serve to inhibit metastasis, alone or in combination with GP IIb/IIIa antagonists. Examples of other fibrinogen receptor antagonists include abciximab, eptifibatide, sibrafiban, lamifiban, lotrafiban, cromofiban, and CT50352.

20

FORMULATION

The salts of the instant invention may be administered to mammals, preferably humans, either alone or, preferably, in combination with pharmaceutically acceptable carriers or diluents, optionally with known adjuvants, such as alum, in a pharmaceutical composition, according to standard pharmaceutical practice. The salts can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.

For oral use of a chemotherapeutic compound according to this invention, the selected salt may be administered, for example, in the form of tablets or capsules, or as an aqueous solution or suspension. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch, and lubricating agents, such as magnesium stearate, are commonly added. For oral administration in capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with

emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents may be added. For intramuscular, intraperitoneal, subcutaneous and intravenous use, sterile solutions of the active ingredient are usually prepared, and the pH of the solutions should be suitably adjusted and buffered. For intravenous use, the total concentration of solutes should be controlled in order to render the preparation isotonic.

If formulated as a fixed dose, combination products, such as those described hereinabove, employ the salts of this invention within the dosage range described below and the other pharmaceutically active agent(s) within its approved dosage range. Salts of the instant invention may alternatively be used sequentially with known pharmaceutically acceptable agent(s) when a combination formulation is inappropriate.

The term "administration" and variants thereof (e.g., "administering" a compound) in reference to a salt of the invention means introducing the salt or a prodrug of the salt into the system of the animal in need of treatment. When a compound of the invention or prodrug thereof is provided in combination with one or more other active agents (e.g., a cytotoxic agent, etc.), "administration" and its variants are each understood to include concurrent and sequential introduction of the salt or prodrug thereof and other agents.

As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

The term "therapeutically effective amount" as used herein means that amount of active salt, or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.

The present invention also encompasses a pharmaceutical composition useful in the treatment of cancer; comprising the administration of a therapeutically effective amount of the salts of this invention; with or without pharmaceutically acceptable carriers or diluents. Suitable compositions of this invention include aqueous solutions comprising salts of this invention and pharmacologically acceptable carriers, e.g., saline, at a pH level, e.g., 7.4.

When a salt according to this invention is administered into a human subject, the daily dosage will normally be determined by the prescribing physician.

with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient's symptoms.

In one exemplary application, a suitable amount of a salt is administered to a mammal undergoing treatment for cancer. Administration occurs in 5 an amount between about 0.1 mg/kg of body weight to about 60 mg/kg of body weight per day, preferably of between 0.5 mg/kg of body weight to about 40 mg/kg of body weight per day.

ASSAYS

10.

The salts of the instant invention described in the Examples were tested by the assays described below and were found to have kinase inhibitory activity. Other assays are known in the literature and could be readily performed by those of skill in the art (see, for example, Dhanabal et al., *Cancer Res.* 59:189-197; 15 Xin et al., *J. Biol. Chem.* 274:9116-9121; Sheu et al., *Anticancer Res.* 18:4435-4441; Ausprung et al., *Dev. Biol.* 38:237-248; Gimbrone et al., *J. Natl. Cancer Inst.* 52:413-427; Nicosia et al., *In Vitro* 18:538-549).

I. VEGF RECEPTOR KINASE ASSAY

20

VEGF receptor kinase activity is measured by incorporation of radio-labeled phosphate into polyglutamic acid, tyrosine, 4:1 (pEY) substrate. The phosphorylated pEY product is trapped onto a filter membrane and the incorporation of radio-labeled phosphate quantified by scintillation counting.

25

Materials

VEGF Receptor Kinase

The intracellular tyrosine kinase domains of human KDR (Terman, B.I. et al. *Oncogene* (1991) vol. 6, pp. 1677-1683.) and Flt-1 (Shibuya, M. et al. 30 *Oncogene* (1990) vol. 5, pp. 519-524) were cloned as glutathione S-transferase (GST) gene fusion proteins. This was accomplished by cloning the cytoplasmic domain of the KDR kinase as an in frame fusion at the carboxy terminus of the GST gene. Soluble recombinant GST-kinase domain fusion proteins were expressed in *Spodoptera frugiperda* (Sf21) insect cells (Invitrogen) using a baculovirus expression 35 vector (pAcG2T; Pharmingen).

The other materials used and their compositions were as follows:

- Lysis buffer: 50 mM Tris pH 7.4, 0.5 M NaCl, 5 mM DTT, 1 mM EDTA, 0.5% triton X-100, 10% glycerol, 10 mg/mL of each leupeptin, pepstatin and aprotinin and 1mM phenylmethylsulfonyl fluoride (all Sigma).
- Wash buffer: 50 mM Tris pH 7.4, 0.5 M NaCl, 5 mM DTT, 1 mM EDTA, 0.05% triton X-100, 10% glycerol, 10 mg/mL of each leupeptin, pepstatin and aprotinin and 1mM phenylmethylsulfonyl fluoride.
- Dialysis buffer: 50 mM Tris pH 7.4, 0.5 M NaCl, 5 mM DTT, 1 mM EDTA, 0.05% triton X-100, 50% glycerol, 10 mg/mL of each leupeptin, pepstatin and aprotinin and 1mM phenylmethylsulfonyl fluoride.
- 10 X reaction buffer: 200 mM Tris, pH 7.4, 1.0 M NaCl, 50 mM MnCl₂, 10 mM DTT and 5 mg/mL bovine serum albumin (Sigma).
- Enzyme dilution buffer: 50 mM Tris, pH 7.4, 0.1 M NaCl, 1 mM DTT, 10% glycerol, 100 mg/mL BSA.
- 10 X Substrate: 750 µg/mL poly (glutamic acid, tyrosine; 4:1) (Sigma).
- Stop solution: 30% trichloroacetic acid, 0.2 M sodium pyrophosphate (both Fisher).
- Wash solution: 15% trichloroacetic acid, 0.2 M sodium pyrophosphate.
- Filter plates: Millipore #MAFC NOB, GF/C glass fiber 96 well plate.
- Method
- A. Protein Purification
1. Sf21 cells were infected with recombinant virus at a multiplicity of infection of 5 virus particles/ cell and grown at 27°C for 48 hours.
 2. All steps were performed at 4°C. Infected cells were harvested by centrifugation at 1000 X g and lysed at 4°C for 30 minutes with 1/10 volume of

lysis buffer followed by centrifugation at 100,000Xg for 1 hour. The supernatant was then passed over a glutathione Sepharose column (Pharmacia) equilibrated in lysis buffer and washed with 5 volumes of the same buffer followed by 5 volumes of wash buffer. Recombinant GST-KDR protein was eluted with wash buffer/10 mM reduced glutathione (Sigma) and dialyzed against dialysis buffer.

- 5 5 glutathione (Sigma) and dialyzed against dialysis buffer.
- B. VEGF Receptor Kinase Assay
- 1) Add 5 μ l of inhibitor or control to the assay in 50% DMSO.
- 2) Add 35 μ l of reaction mix containing 5 μ l of 10 X reaction buffer, 5 μ l 25
10 mM ATP/10 μ Ci [³³P]ATP (Amersham), and 5 μ l 10 X substrate.
- 3) Start the reaction by the addition of 10 μ l of KDR (25 nM) in enzyme dilution
buffer.
- 4) Mix and incubate at room temperature for 15 minutes.
- 5) Stop by the addition of 50 μ l stop solution.
- 15 6) Incubate for 15 minutes at 4°C.
- 7) Transfer a 90 μ l aliquot to filter plate.
- 8) Aspirate and wash 3 times with wash solution.
- 9) Add 30 μ l of scintillation cocktail, seal plate and count in a Wallac Microbeta
scintillation counter.

20

II. HUMAN UMBILICAL VEIN ENDOTHELIAL CELL MITOGENESIS ASSAY

Human umbilical vein endothelial cells (HUVECs) in culture proliferate in response to VEGF treatment and can be used as an assay system to quantify the effects of KDR kinase inhibitors on VEGF stimulation. In the assay described, 25 quiescent HUVEC monolayers are treated with vehicle or test compound 2 hours prior to addition of VEGF or basic fibroblast growth factor (bFGF). The mitogenic response to VEGF or bFGF is determined by measuring the incorporation of [³H] thymidine into cellular DNA.

30 **Materials**

HUVECs: HUVECs frozen as primary culture isolates are obtained from Clonetics Corp. Cells are maintained in Endothelial Growth Medium (EGM; Clonetics) and are used for mitogenic assays described in passages 3-7 below.

35

Culture Plates: NUNCLON 96-well polystyrene tissue culture plates (NUNC #167008).

- Assay Medium: Dulbecco's modification of Eagle's medium containing 1 g/mL glucose (low-glucose DMEM; Mediatech) plus 10% (v/v) fetal bovine serum (Clonetics).
- 5

- Test Compounds: Working stocks of test compounds are diluted serially in 100% dimethylsulfoxide (DMSO) to 400-fold greater than their desired final concentrations.
- 10 Final dilutions to 1X concentration are made directly into Assay Medium immediately prior to addition to cells.

10X Growth Factors: Solutions of human VEGF165 (500 ng/mL; R&D Systems) and bFGF (10 ng/mL; R&D Systems) are prepared in Assay Medium.

- 15 10X [³H]Thymidine: [Methyl-³H]thymidine (20 Ci/mmol; Dupont-NEN) is diluted to 80 µCi/mL in low-glucose DMEM.

- 20 Cell Wash Medium: Hank's balanced salt solution (Mediatech) containing 1 mg/mL bovine serum albumin (Boehringer-Mannheim).

Cell Lysis Solution: 1 N NaOH, 2% (w/v) Na₂CO₃.

Method

- 25
1. HUVEC monolayers maintained in EGM are harvested by trypsinization and plated at a density of 4000 cells per 100 µL Assay Medium per well in 96-well plates. Cells are growth-arrested for 24 hours at 37°C in a humidified atmosphere containing 5% CO₂.
 2. Growth-arrest medium is replaced by 100 µL Assay Medium containing either vehicle (0.25% [v/v] DMSO) or the desired final concentration of test compound. All determinations are performed in triplicate. Cells are then incubated at 37°C with 5% CO₂ for 2 hours to allow test compounds to enter cells.

3. After the 2-hour pretreatment period, cells are stimulated by addition of 10 µL/well of either Assay Medium, 10X VEGF solution or 10X bFGF solution. Cells are then incubated at 37°C and 5% CO₂.
 4. After 24 hours in the presence of growth factors, 10X [3H]thymidine (10 µL/well) is added.
 5. Three days after addition of [3H]thymidine, medium is removed by aspiration, and cells are washed twice with Cell Wash Medium (400 µL/well followed by 200 µL/well). The washed, adherent cells are then solubilized by addition of Cell Lysis Solution (100 µL/well) and warming to 37°C for 30 minutes. Cell lysates are transferred to 7-mL glass scintillation vials containing 150 µL of water. Scintillation cocktail (5 mL/vial) is added, and cell-associated radioactivity is determined by liquid scintillation spectroscopy.
- Based upon the foregoing assays the salts of the instant invention are inhibitors of VEGF and thus are useful for the inhibition of angiogenesis, such as in the treatment of ocular disease, e.g., diabetic retinopathy and in the treatment of cancers, e.g., solid tumors. The instant salts inhibit VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC₅₀ values between 0.01 - 5.0 µM. These salts may also show selectivity over related tyrosine kinases (e.g., FGFR1 and the Src family; for relationship between Src kinases and VEGFR kinases, see Eliceiri et al., Molecular Cell, Vol. 4, pp.915-924, December 1999).

III. FLT-1 KINASE ASSAY

Flt-1 was expressed as a GST fusion to the Flt-1 kinase domain and was expressed in baculovirus/insect cells. The following protocol was employed to assay compounds for Flt-1 kinase inhibitory activity:

- 1) Inhibitors were diluted to account for the final dilution in the assay, 1:20.
- 2) The appropriate amount of reaction mix was prepared at room temperature:
 - 10X Buffer (20 mM Tris pH 7.4/0.1 M NaCl/1mM DTT final)
 - 0.1M MnCl₂ (5mM final)
 - pEY substrate (75 µg/mL)
 - ATP/[³³P]ATP (2.5 µM/1 µCi final)
 - BSA (500 µg/mL final).

- 3) 5 µL of the diluted inhibitor was added to the reaction mix. (Final volume of 5 µL in 50% DMSO). To the positive control wells, blank DMSO (50%) was added.
- 4) 35 µL of the reaction mix was added to each well of a 96 well plate.
- 5) Enzyme was diluted into enzyme dilution buffer (kept at 4°C).
- 6) 10 µL of the diluted enzyme was added to each well and mix (5 nM final). To the negative control wells, 10 µL 0.5 M EDTA was added per well instead (final 100 mM).
- 7) Incubation was then carried out at room temperature for 30 minutes.
- 10) 8) Stopped by the addition of an equal volume (50 µL) of 30% TCA/0.1M Na pyrophosphate.
- 9) Incubation was then carried out for 15 minutes to allow precipitation.
- 10) Transferred to Millipore filter plate.
- 11) Washed 3X with 15% TCA/0.1M Na pyrophosphate (125 µL per wash).
- 15) 12) Allowed to dry under vacuum for 2-3 minutes.
- 13) Dried in hood for about 20 minutes.
- 14) Assembled Wallac Millipore adapter and added 50 µL of scintillant to each well and counted.

20 IV. FLT-3 KINASE ASSAY

Flt-3 was expressed as a GST fusion to the Flt-3 kinase domain, and was expressed in baculovirus/insect cells. The following protocol was employed to assay compounds for Flt-3 kinase inhibitory activity:

- 25) 1) Dilute inhibitors (account for the final dilution into the assay, 1:20)
- 2) Prepare the appropriate amount of reaction mix at room temperature.
 - 10X Buffer (20 mM Tris pH 7.4/0.1 M NaCl/1mM DTT final)
 - 0.1M MnCl₂ (5mM final)
 - pEY substrate (75 µg/mL)
 - ATP/[³³P]ATP (0.5 µM/L µCi final)
 - BSA (500 µg/mL final)
- 30) 3) Add 5 µL of the diluted inhibitor to the reaction mix. (Final volume of 5 µL in 50% DMSO). Positive control wells - add blank DMSO (50%).
- 4) Add 35 µL of the reaction mix to each well of a 96 well plate.
- 35) 5) Dilute enzyme into enzyme dilution buffer (keep at 4°C).

- 6) Add 10 µL of the diluted enzyme to each well and mix (5-10 nM final).
Negative control wells – add 10 µL 0.5 M EDTA per well instead (final 100 mM)
- 7) Incubate at room temperature for 60 minutes.
- 5 8) Stop by the addition of an equal volume (50 µL) of 30% TCA/0.1M Na pyrophosphate.
- 9) Incubate for 15 minutes to allow precipitation.
- 10) Transfer to Millipore filter plate.
- 11) Wash 3X with 15% TCA/0.1M Na pyrophosphate (125 µL per wash).
- 10 12) Allow to dry under vacuum for 2-3 minutes.
- 13) Dry in hood for about 20 minutes.
- 14) Assemble Wallac Millipore adapter and add 50 µL of scintillant to each well and count.

15

EXAMPLES

Examples provided are intended to assist in a further understanding of the invention. Particular materials employed, species and conditions are intended to be further illustrative of the invention and not limiting of the reasonable scope thereof.

25

The free bases used to prepare the salts of this invention may be obtained by employing the procedures described below, as well as those described in WO 01/17995, published March 15, 2001, hereby incorporated by reference. In addition, other procedures may be used such as standard manipulations of reactions that are known in the literature.

HPLC Methods Used:


	HPLC Analysis:	Isocratic method (for solubility studies)
30	Analysis Method (HPLC):	Chromatographic Conditions
	Column:	BDS HYPESIL, C18 (250 mm x 46 mm), 5µm particle size
	Column Temperature:	ambient
	Detector:	230nm (UV wavelength)
35	Column Temp.	Ambient

Flow Rate:	1.0 mL/ min
Injection Volume:	20 µL
Mobile Phase:	A) 0.1% Phosphoric Acid B) 100% Acetonitrile
5 Diluent:	50% Acetonitrile-DI water
Gradient Profile:	(A/B) starts from (60/40) and stays at (60/40) for 10 minutes.
Run Time:	10 minutes

10


SCHEME 1

Synthesis of 2-chloro-thiazole-5-carbonitrile (**1-2**)



2-Chloro-thiazole-5-carbonitrile (1-2)

15 A flame dried round bottom flask under N₂ was charged with 150 mL
anhydrous MeCN: CuCl₂ (12.9g, 95.9 mmol, 1.2 equiv) was added and the reaction
was maintained in a room temperature bath. tert-Butylnitrite (14.3 mL, 120 mmol,
1.5 equiv) was added gradually over 10 minutes. After 10 minutes, 2-amino-thiazole-
5-carbonitrile (**1-1**, 10.0g, 79.9 mmol) was added as a solid gradually. The reaction
was stirred at room temperature for 4 hours. The reaction was poured into 400 mL
20 0.5M HCl (aq). The mixture was extracted 3x with EtOAc. The organic phases
were dried over Na₂SO₄, filtered and concentrated to afford pure desired product.
1H NMR (CDCl₃) δ 8.04 (s)

SCHEME 2Synthesis of 4-(t-butyl-dimethyl-silanyloxymethyl)-pyridin-2-ylamine (2-5)

5

2-Acetylaminoisonicotinic acid (2-2)

N-(4-Methyl-pyridin-2-yl)-acetamide, 70g (466 mmol) was stirred in 400 mL water. The mixture was warmed to 80°C. KMnO₄ (368g, 2.33 mol, 5 equiv) was added dissolved in water over 45 minutes. The solution was heated to reflux for 3 hours. The reaction was then cooled and filtered. The filtrate was concentrated *in vacuo* to afford the desired product. ¹H NMR (CD₃OD) δ 8.62 (s, 1H), 8.42 (d, 1H, J = 5.1 Hz), 7.59 (dd, 1H, J = 5.1 Hz), 2.19 (s, 3H).

2-Amino-isonicotinic acid methyl ester (2-3)

2-Acetylaminoisonicotinic acid (3.10g, 17.2 mmol) was stirred in 35 mL MeOH at 0°C. HCl (g) was bubbled through the solution for 10 minutes and then the reaction was heated to reflux. After 16 hours the reaction was concentrated *in vacuo*. The residue was diluted with water and the pH was adjusted to 7 with Na₂CO₃ (s). A white precipitate formed which was filtered to afford a portion of pure desired product. The aqueous phase was extracted three times with 95:5 dichloromethane (DCM)/nBuOH. The organic phases were dried over Na₂SO₄, filtered and concentrated to afford more of the pure product as a white solid.


¹H NMR (CDCl₃) δ 8.19 (d, 1H, J = 5.3 Hz), 7.17 (dd, 1H, J = 1.4, 5.3 Hz), 7.07 (d, 1H, J = 1.3 Hz), 4.64 (bs, 2H), 3.92 (s, 3H). MS [M+H]⁺ = 153.0.

(2-Amino-pyridin-4-yl)-methanol (2-4)

5 2-Amino-isonicotinic acid methyl ester (6.0g, 39.4 mmol) was dissolved in 80 mL anhydrous THF in a flame dried round bottom flask under nitrogen gas. The solution was cooled to -45°C and LAH (39.4 mL, 1M in THF) was added slowly. The reaction was allowed to warm to 0°C and was quenched by the addition of 15 mL of 1M NaOH (aq). The solution was filtered and the solid
10 was washed with THF. The filtrate was concentrated to afford the pure product.
¹H NMR (DMSO-d₆) δ 7.79 (d, 1H, J = 5.2 Hz), 6.41 (s, 1H), 6.38 (d, 1H, J = 5.9 Hz), 5.79 (bs, 2H), 5.19 (t, 2H, J = 5.7), 4.35 (d, 2H, J = 5.6 Hz).

4-(tert-Butyl-dimethyl-silanyloxymethyl)-pyridin-2-ylamine (2-5)

15 (2-Amino-pyridin-4-yl)-methanol (4.68 g, 37.7 mmol) was dissolved in 40 mL anhydrous DMF under N₂. Imidazole (2.57 g, 37.7 mmol, 1 equiv) was added followed by the addition of TBSCl (5.68g, 37.7 mmol, 1 equiv). After 2 hours the reaction was quenched by the addition of water. A precipitate formed which was filtered to afford pure desired product. The aqueous filtrate was extract 3x with EtOAc. The organic phases were dried over Na₂SO₄, filtered and concentrated to afford additional impure material. ¹H NMR (CDCl₃) δ 7.99 (d, 1H, J = 5.8 Hz), 6.57 (d, 1H, J = 5.1 Hz), 6.51 (s, 1H), 4.64 (s, 2H), 4.40 (bs, 2H), 0.95 (s, 9H), 0.11 (s, 6H).

SCHEME 3Synthesis of 2-(4-chloromethyl-pyridin-2-ylamino)-thiazole-5-carbonitrile (3-3)

5 2-[4-(tert-Butyl-dimethyl-silyloxy)methyl]-pyridin-2-ylamino]-thiazole-5-carbonitrile (3-1)

4-(tert-Butyl-dimethyl-silyloxy)methyl-pyridin-2-ylamine (2-5, 5.94 g, 24.9 mmol) was dissolved in 50mL anhydrous tetrahydrofuran (THF) under N₂. NaH (60% suspension, 2.99g, 74.8 mmol, 3 equiv) was added (vigorous bubbling occurred) and the resulting mixture was stirred for 15 minutes. 2-Chloro-thiazole-5-carbonitrile (1-2, 4.32g, 29.9 mmol) was added and the reaction was heated to reflux. After 2 hours the reaction was cooled and was quenched by the addition of water. The THF was removed *in vacuo* and the resulting aqueous solution was adjusted to pH = 7 by the addition of 1M HCl (aq). The resulting precipitate was filtered and washed with water to provide reasonably pure product.¹H NMR (CDCl₃) δ 10.32 (bs, 1H), 8.33 (d, 1H, J = 5.3 Hz), 7.99 (s, 1H), 6.96 (s, 1H), 6.91 (d, 1H, J = 5.3 Hz), 4.78 (s, 2H), 0.98 (s, 9H), 0.16 (s, 6H).

2-(4-Hydroxymethyl-pyridin-2-ylamino)-thiazole-5-carbonitrile (3-2)

20 2-[4-(tert-Butyl-dimethyl-silyloxy)methyl]-pyridin-2-ylamino]-thiazole-5-carbonitrile (1.30g, 3.75 mmol) was dissolved in 10 mL anh THF. Hydrogen-fluoride (Aldrich, 5.0 mL) was added and the reaction was stirred for 20 minutes. The bulk of the solvent was removed *in vacuo* and the resulting residue was diluted with half-saturated NaHCO₃ (aq). A precipitate formed


which was filtered and washed with water to afford the titled compound. ^1H NMR (DMSO-d₆) δ 12.23 (bs, 1H), 8.30 (d, 1H, J = 5.3 Hz), 8.26 (s, 1H), 7.15 (s, 1H), 6.99 (d, 1H, J = 5.3 Hz), 5.49 (t, 1H, J = 5.7 Hz) 4.54 (d, 2H, J = 5.7 Hz).

5 2-(4-Chloromethyl-pyridin-2-ylamino)-thiazole-5-carbonitrile (3-3)

2-(4-Hydroxymethyl-pyridin-2-ylamino)-thiazole-5-carbonitrile (0.883g, 3.80mmol) was stirred in anhydrous CH₂Cl₂ (12mL) under N₂. Dimethylformamide (0.354 mL, 3.80 mmol, 1 equiv) was added followed by the addition of phosphorous oxychloride (0.294 mL, 3.80 mmol). After 4 hours the reaction was concentrated and quenched by the addition of saturated NaHCO₃ (aq). A precipitate formed which was filtered and washed with water to provide the titled compound. ^1H NMR (DMSO-d₆) δ 12.35 (bs, 1H), 8.40 (d, 1H, J = 5.3 Hz), 8.28 (s, 1H), 7.20 (s, 1H), 7.12 (d, 1H, J = 5.3 Hz), 4.82 (s, 2H).

SCHEME 4

Synthesis of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide (**4-4**)




To a solution of Boc-piperazine, **4-1**, in CH₂Cl₂ (200 mL) was added 6.74 g (1 equiv) methylisocyanate in CH₂Cl₂ (50 mL). The reaction mixture was stirred at room temperature for 6 hours and another 0.25 eq (1.69 g) of methylisocyanate was added. The reaction mixture was then stirred at room temperature overnight. The reaction was subsequently quenched with water (75 mL) and extracted with CH₂Cl₂ (3 X 50 mL). The combined organics were dried over Na₂SO₄, filtered, and concentrated to afford **4-2** as a white solid. ¹H NMR (CDCl₃) δ 4.44 (bs, 1H), 3.48-3.33 (m, 8H), 2.82 (d, 3H, J = 4.58), 1.47 (s, 9H).

to warm to room temperature and was stirred for 4 hours. The mixture was then concentrated to afford 1-[(methylamino)carbonyl]piperazin-4-iium chloride, the HCl salt of **4-3**, as an off white solid. ^1H NMR (DMSO-d₆) δ 9.28 (bs, 1H), 7.94 (bs, 1H), 3.52 (m, 4H), 3.01 (m, 4H), 2.57 (s, 3H).

- 5 **2-(4-Chloromethyl-pyridin-2-ylamino)-thiazole-5-carbonitrile 3-3**
 (8.00g, 31.9 mmol) was stirred in 60 mL DMSO. 1-[(Methylamino)carbonyl]
 piperazin-4-iium chloride (11.5 g, 63.8 mmol) was added, followed by addition of
 triethylamine (13.34 mL, 95.7 mmol). The reaction was allowed to stir at room
 temperature for 15 hours, at which time an additional 2.00g piperazine hydrochloride
 10 (11.1 mmol) was added. No further progress was observed so the reaction was
 warmed to 45°C but there was still no further progress. The reaction was cooled to
 room temperature. An additional 6.6 mL Et₃N (48 mmol) was then added. After an
 additional hour, the reaction was diluted with 300mL water. The resulting precipitate
 15 was filtered, washed with water and air dried. The solid was purified by flash
 chromatography (eluted with 92:8 DCM/MeOH) to afford the product **4-4**. ^1H NMR
 (DMSO-d₆) δ 12.20 (bs, 1H), 8.32 (d, 1H, J = 5.49 Hz), 8.26 (s, 1H), 7.13 (s, 1H),
 7.03 (d, 1H, J = 5.19 Hz), 6.42 (bd, 1H, J = 4.27 Hz), 3.52 (s, 2H), 3.29 (m, 4H), 2.51
 (d, 3H, J = 4.27 Hz), 2.33 (m, 4H). [M+H]⁺ = 358.1443.

20

SCHEME 5

25

Bromine (2.88 Kg, 18.0 mole) is added to a solution of 3-methoxyacrylonitrile (1.50 Kg, 18.0 mole, mixture of cis-/trans-isomers) in acetonitrile (3.00 L) at 5-10 °C. The mixture is aged for 20 minutes, then pre-cooled water (about 5 °C, 12.0 L) is added and vigorous stirred for 1 hour.

NaOAc•3H₂O, (2.21 Kg, 16.2 mole, 0.90 equiv.) is added and stirred for 15 minutes and then thiourea (1.51 Kg, 19.80 mole, 1.10 equiv.) is added (endothermic dissolution followed by about 10-15 °C exotherm in about 0.5h). The mixture is aged at 15 °C for 1.5 hour, then more NaOAc•3H₂O (1.47 Kg, 0.60 equiv.)

is added. It is slowly heated to 60 °C in 1 hour and aged for 3 hours at 60 °C then cooled to 10°C.

- NaOH (10 N, 1.13 L, 0.625 equiv.) is added to adjust the pH to 3.8-4.0. After aging for 1 hour, the product is filtered and washed with water (11.5 L). Drying 5 give 1.86 Kg of the crude aminothiazole as a brown solid.

- The crude product is dissolved into acetone (35 L) at 50 °C and treated with Darco KB-B (380 g) for 2 hours. It is filtered through a Solka-Floc pad and then rinsed with acetone (5 L). The filtrate is concentrated in vacuo to about 7 L (about 5 L residue acetone). Heptane (10 L) is added in 0.5 hour and the slurry is aged for 1 hour. 10 The product is filtered and the filter cake is washed with 2/1 heptane/acetone (6 L). Drying at rt affords 1.72 Kg of the aminothiazole as a pinkish solid.


HPLC conditions: Ace-C8 4.6x250mm column; linear gradient: 5-80% MeCN in 12 minutes, 0.1% H₃PO₄ in the aqueous mobile phase; Flow rate: 1.50ml/min; UV detection at 220nm.

15

SCHEME 6

Preparation of 9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene, Xantphos

20



25

To a 1L RBF are added MTBE (500 mL), 9,9-dimethylxanthene


(26.65g) and TMEDA (30.6g). After degassing the solution, *s*-BuLi (155 g, 1.3 M in cyclohexane) is cannulated into a dropping funnel and then slowly added over 30 min while maintaining the batch temperature at 10-20 °C. The mixture is then aged for 16 h at room temperature. Ph₂PCl is added slowly via a dropping funnel while maintain the mildly exothermic reaction at 10-20 °C.

30

Approximately 60% of the Ph₂PCl (30mL) is added in 0.5 hour. The mixture is aged for 15 minutes before addition of the remaining Ph₂PCl. After aged for 5.5 h at room temperature, the reaction is quenched with MeOH (2.0 mL). The

product is filtered and the slightly yellow solid is washed consecutively with MeOH (200mL), water (200mL), MeOH (200mL) and MTBE (200mL) and dried to give an off-white solid as product.


5

SCHEME 7

A slurry of 2-chloro-4-formylpyridine (1.49 Kg, 10.5 mole, 1.05 equiv), 2-aminothiazole (1.27 Kg, 10.0 mole, 1.0 equiv), K_3PO_4 (2.34 Kg, 11.0 mole, 1.1 equiv) in toluene (20 L) is degassed by two vacuum/nitrogen cycles. $\text{Pd}_2(\text{dba})_3$ (114.5g, 0.125 mmol, 2.5mol% Pd) and Xantphos (159 g, 0.275 mole, 2.75mol%) are then added and the mixture is degassed by one vacuum/nitrogen cycle followed by bubbling nitrogen through the slurry for 10 minutes. The mixture is heated to 60°C and degassed water (90 mL, 5.0 mole, 0.5 equiv) was added over 5 minutes. The mixture is then heated to 90°C and aged for 8 h.

It is cooled to rt and filtered. The filter cake is washed with toluene (20 L) until very little DBA is observed in the wash. DMAc (24 L) is added to the filter cake to dissolve the product. The insoluble is filtered off and washed with more DMAc (6 L). The filtrate is acidified with concentrate HCl (110 mL) to pH 2.7. Water (3 L) is added and the mixture is concentrated at 40-50 $^\circ\text{C}$ under vacuum to remove most of the residual toluene by azeotropic distillation. More water (3 x 1L) is added as the distillation progress.


The mixture is seeded and then water (13 L) is added at a rate of about 1.3 L/h. The product is filtered and washed with 5/4 DMAc/water (4.0 L x 2), water (4.0 L), acetone (4 L x 2), and then oven dried at 40C under vacuum (100mmHg) with nitrogen sweep to give the product.

SCHEME 8Preparation of N-benzyl-N'-methylaminocarbonylpiperazine dihydrate


5

To a 50-L 3-neck RBF is added H₂O (6.0 L) followed by K₂CO₃ (4.56 Kg) with stirring. It is cooled to 10 °C. Acetonitrile (12 L) and methylamine (40wt% in water, 1.40 Kg) are added and the mixture is cooled to 0-5 °C. Phenyl chloroformate (2.59 Kg) is then added as quickly as possible while maintaining the exothermic reaction at <15 °C. 1-Benzylpiperazine is added 15 min after addition of phenyl chloroformate and the biphasic mixture is heated to 70 °C. After aging for 1 h at 70 °C, the reaction mixture was concentrated under vacuum to remove most of the MeCN.

15 NaOH (7.5L 5 N NaOH) is added and the mixture is seeded. The suspension is then cooled to rt and aged for 1hour. The product is filtered and the filter cake is washed with cold NaOH (0.5 N aq, 4 L x 2) and then ice-cold water (4 L x 2). It is purified by recrystallization from toluene (15 L) to remove any dibenzylpiperazine impurity. NaOH is used to remove phenol.

SCHEME 9Preparation of N-methylaminocarbonylpiperazine hydrochloride

- 5 HCl (74 mL 12 N, 0.10 eq) is added to MeOH (7 L) and then piperazine urea 1 (2.69 Kg, 10.0 mol) is added. The mixture is hydrogenated using 5% Pd/C (180 g) under 40psi of hydrogen pressure at 40 °C for 18 h. Pd/C is slurried in MeOH (1 L) and transferred by vacuum. The SM container is rinsed with MeOH (1 L).
- 10 After confirming the completion of the reaction, the mixture is filtered through a pad of Solka-Floc and washed with MeOH (2 L) then IPA (4 L). The colorless solution is concentrated to about 5-6 L at about 40 °C under vacuum. IPA (5 L) is added followed by HCl (12 N aq, 0.767 L, 0.92 eq) until the pH of the solution becomes about 3. The mixture is then concentrated under vacuum and flushed with more IPA (5 + 5 L) to a final volume of 6 L. KF of the supernatant should be <1w% water. It is then aged at 15 °C for 5 h.
- 15 The resulting white crystals are filtered and washed with IPA (4 L). It is then dried in a vacuum oven at 40 °C with slow nitrogen sweep to give product 2.

SCHEME 10


To a slurry of the pyridine aldehyde (2.19 Kg, 94.5w%, 9.00 mole) and
 5 the piperazine urea HCl salt (1.79 Kg, 9.90 mmol) in DMAc (13.5 L) is added Et_3N
 (1.00 Kg, 9.90 mole) followed by acetic acid (2.16 Kg, 36.0 mole) with cooling (15
 °C). After aging for 0.5 h, NaBH(OAc)_3 (2.29 Kg, 10.8 mole) is added in 8 portions
 (25minutes/portion).

The mixture is stirred for 1 hour and the completion of the reaction
 10 confirmed by HPLC. Water (6.8 L) is added slowly (14 h) to complete the
 crystallization. Seed with monohydrate of the free base after about 1-2 L of water has
 been added.

The product is filtered after aging for 3 hours and the filter cake
 washed with 3/2 DMAc/water (6.7 L), then 1/1 acetone/water (6 L) then acetone (2 x
 15 4 L). Oven drying at 40 C with slow nitrogen sweep afforded the free base of
 Compound 4-4.

Compound 4-4 (4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-
 20 piperazine-1-carboxylic acid methylamide) was studied as crystalline HCl, besylate,
 citrate and tartrate salts.

The structure of the free base of **4-4** is shown below:



The free base form of **4-4** has the molecular formula C₁₆H₁₉N₇OS
 5 and a molecular weight of 357.44.

I. Hydrochloride Salt forms of 4-4 (Forms C, D, E and F):

A sample of the free base of compound **4-4** (503 mg, 1.41 mmol) was dissolved in MeOH. Aqueous HCl (4M, 0.352 ml) was added and the mixture was stirred. A precipitate started to form and the mixture was concentrated in vacuo. The resulting solid was dried at 60°C for 24 h to remove residual solvent. This provided Form **C** as a white solid.

A solution of crude free base of Compound **4-4** (1.91 g 1.79g assay) in DMAc (18 mL) is treated with Darco G60 (0.36 g) for 3 hours. The Darco is filtered off and rinsed with DMAc (2 mL). Concentrated HCl (0.20 mL) is added and the mixture is aged until crystallization occurred. The remaining portion of concentrate HCl (0.25 mL) is added over 3 hours. The mixture is aged for 3 hours and filtered. The filter cake is rinsed with DMAc (3 mL) then acetone (10 mL). Drying under nitrogen gives the anhydrous Compound **4-4** HCl salt.

Anhydrous HCl salt of Compound **4-4** (1.50g) is suspended in 2/1 acetone/water (9 mL) for 3 hours. More acetone (6 mL) is added and the mixture is aged for 2 hour then filtered. The solid is rinsed with acetone (5 mL) and air dried to give the HCl salt monohydrate (Form **D**) of Compound **4-4**.

A sample of the free base of compound **4-4** (1.00 g, 2.97 mmol) was suspended in 200ml 1:1 methanol/water. Aqueous HCl (1M, 2.97ml, 2.97mmol) was added and the suspension became a solution. 0.5 g activated carbon was added and the mixture was stirred for 30 minutes. The mixture was then filtered through a pad of celite and washed with 1:1 Methanol/Water. The filtrate was concentrated to dryness to give Form **E** of the HCl salt as a white solid.

The hydrochloride salt form of **4-4** has the molecular formula C₁₆H₂₀N₇OSCl and a molecular weight of 393.901.

Microscopic Characteristics

5 Microscopic evaluation shows irregularly shaped particles of approximately 3-25 microns, which are birefringent under plane polarized light.

X-Ray Powder Diffraction (XRPD)

10 Three different forms of the HCl salt were observed and are designated as Form **C**, Form **D** and Form **E**. The X-ray powder diffraction pattern of the hydrochloride salt (Figures 1-3) is indicative of a crystalline material with multiple diffraction peaks between 2° and 30° 2-theta.

Thermal Properties

15

DSC

20 DSC of the hydrochloride salt (Form **C**) from 20°C to 350°C at a heating rate of 5°C/min. shows a melting endotherm at 273°C. The DSC of Form **D** shows an irreversible loss of water between 50 and 175°C, and a melting transition at 264°C, at a heating rate of 5°C/min. Form **E** shows a melting endotherm at 246°C, at a heating rate of 10°C/min.

TGA

25 TGA of the hydrochloride salt (Form **C**) from 20°C to 400°C at a heating rate of 10°C/min. shows a weight loss of 4.26% between 20°C and 125°C. The TGA trace for Form **D** shows a 4.3% wt. loss between 25 and 125°C suggesting that the HCl Form **D** is a monohydrate (the theoretical weight loss upon dehydration of an HCl monohydrate is 4.37%). The DSC and TGA suggest that Form **E** is also a monohydrate.

30

Hygroscopicity

The hygroscopicity of the hydrochloride salt (Form **C**) was determined at 25°C using a step isotherm program for relative humidities from 0 to 95% RH following drying at 40°C/0%RH for two hours. The hydrochloride salt (Form **C**) is

not hygroscopic at 25°C and picks up about 0.6% moisture at 90%RH. The hygroscopicity of Form **D** was determined at 25°C using a step isotherm program with RH from 0 to 95% following drying at 50°C/0% RH for 2 hours. The HCl monohydrate **D** was slightly hygroscopic gaining 3.7% wt. at 75% RH. The 5 hygroscopicity of Form **E** was determined at 25°C. The HCl form **E** was stable under the pre-drying conditions, and non-hygroscopic (gaining 1.06% wt. at 75% RH).

Solubility

10 The solubility of the hydrochloride salt of **4-4** at room temperature was determined in water and several organic solvents that can be used in pharmaceutical processing. The solubility results for Form **C** are tabulated in Tables I.

Table I: Solubility of Hydrochloride Salt (Form **C) in Different Organic Solvents**

Solvent	Solubility (mg/mL)
Water ¹	6.0
50% aqueous Ethanol	10.4
50% aqueous IPA	12.3

1) The native pH in water 2.90

15

The solubility of the HCl form **D** in water is 1.9 mg/mL at pH 2.1. The suspended solids were recovered and analyzed by XRPD. Form **D** retains the same form after 3-week suspension in water. However, we observed that the HCl Form **E** converted to Form **D** after suspension in water.

20

Dehydration of the HCl monohydrate **D** to Form **F**:

The HCl form **D** was further evaluated by hot-stage XRPD (Figure 4). The salt Form **D** retained its form at 100°C, but changed to a different anhydrous form 25 (Form **F**) at 175°C. The dehydrated HCl salt (Form **F**) remains anhydrous upon storage at 25°C and ambient RH. The HCl salt form **D** was also dehydrated under vacuum. However, elevated temperature (140°C) was required to achieve the dehydration. The DSC, TGA and elemental analysis confirm the dehydration of the monohydrate. No thermal events were observed below 200°C for the dehydrated HCl 30 salt (Form **F**) and a melting endotherm was seen at 265°C, at a heating rate of

5°C/min. Moisture sorption experiments at 25°C suggest that the dehydrated HCl (Form F) is nonhygroscopic.

- The HCl monohydrate form D was recrystallized from acetonitrile.
- 5 The form of the solids recovered from these experiments was identical to the dehydrated HCl salt (Form F) observed in the hot stage XRPD (Figure 4). The solubility of the dehydrated HCl salt (Form F) is 5.7 mg/mL and the resulting pH of the solution is 2.7. When the dehydrate (Form F) was suspended in water for 2 days, no conversion to the monohydrate (Form D) was observed. However, a sample that
10 was suspended in water for 2 weeks showed a complete conversion to the monohydrate (Form D).

Hydrochloride Ethanolate

- The HCl monohydrate D was also dehydrated via suspension in hot ethanol. A new form, the hydrochloride ethanolate, was discovered which was characterized by XRPD (Figure 5), DSC and TGA. The TGA shows a 6.4 % wt. loss at 150-210°C (the theoretical weight loss upon the dehydration of an HCl monoethanolate is 10.5%), suggesting that the new form might be a hemi-ethanolate. For the HCL ethanolate a melting endotherm was seen at 268°C, at a heating rate of
15 5°C/min. When this form was suspended in water, the new form converted back to the HCl monohydrate D.

II. Tartrate Salt:

- 1.10 g (3.08 mmol) of free base of Compound 4-4 was stirred in a
25 suspension with 210 ml 1:1 MeOH/Water. 1 equivalent (0.4618 g, 3.077 mmol) of L-tartaric acid was then added. The suspension was heated to 100°C at which point all of the solids dissolve. The solution was allowed to stir for fifteen minutes, and at that point 0.65 g of activated carbon was added to remove color. The solution was allowed to stir at 100°C for another 30 minutes. The solution was filtered warm
30 (at about 80°C) through a pad of celite. The celite was then washed with warm 1:1 MeOH/Water. The solution was then allowed to cool overnight on the bench top, and in the morning was put in the freezer to complete recrystallization. The solid was then filtered and washed with cold 1:1 MeOH/Water.

Microscopic Characteristics

The tartrate salt was characterized by optical microscopy and is birefringent under cross-polarized light.

5 X-Ray Powder Diffraction (XRPD)

The XRPD pattern of the tartrate salt shows that the salt is crystalline. (Figure 6).

Thermal Properties

10

DSC

The DSC of the tartrate salt shows a melting endotherm at 150°C and decomposition above 175°C, at a heating rate of 10°C/min.

15 TGA

The TGA shows 6.4% wt. loss between 50 and 145°C suggesting that the tartrate salt might be a dihydrate (the theoretical weight loss upon dehydration of one monohydrate is 3.43%).

20 Hygroscopicity

The tartrate salt is nonhygroscopic, gaining 0.75% wt. at 75% RH.

Solubility

25 The solubility of the tartrate salt in water is 0.31 mg/mL and the pH of the resulting aqueous solution is 3.6. The solid suspended in water for 3 weeks was recovered, and no change in forms was observed by XRPD.

III. Citrate Salts (Forms G, H and I):

30

A sample of the free base of compound 4-4 (1.10 g, 3.08 mmol) was suspended in 210ml 1:1 methanol/water. Citric Acid (0.591 g, 3.08 mmol) was added. The suspension was then heated to 100°C to form a solution. Activated carbon (0.65 g) was then added and the solution was stirred at 100°C for 30 minutes.

35 The solution was filtered warm through a pad of celite and washed with a small

amount of warm 1:1 methanol/water. The solution was cooled and stripped to 5-10ml. The remaining 5-10ml was allowed to sit at room temperature overnight to form recrystallized solid. The solid was filtered and washed with cold 1:1 methanol/water. The concentrating and filtering was repeated three more times to 5 recover the recrystallized Form **G** as a white solid.

10 To a suspension of the free base monohydrate of Compound **4-4** (2.60g) in EtOH (30 mL) is added an aqueous solution of citric acid (57%, 2.19mL or 2.69g) over 3 hours. The mixture is stirred for about 4 more hours and filtered. The filter cake is rinsed with EtOH (10mL) and then air dried to give the citrate salt monohydrate (Form **H**) as a white solid.

15 Form **G** or Form **H** converts to Form **I** when either Form is suspended in water for three weeks.

15

Microscopic Characteristics

The citrate salts are birefringent under cross-polarized light.

X-Ray Powder Diffraction (XRPD)

20 The XRPD patterns of the citrate salts show that both forms are highly crystalline. Three forms (Forms **G**, **H** and **I**) have been identified based on the XRPD data. (Figures 7-9).

Thermal Properties

25

DSC

30 The DSC of Form **G** shows two endotherms before the melting endotherm at 153°C, at a heating rate of 10°C/min. The DSC of Form **H** shows one endotherm at 60°C before the melting endotherm at 164°C, at a heating rate of 5°C/min.

TGA

35 The TGA for Form **G** shows a 4.2% wt. loss between 25 and 145°C suggesting that the citrate Form **G** may be a monohydrate (the theoretical weight loss upon dehydration of a citrate monohydrate is 3.17%). The TGA for Form **H** shows a

6.6% wt. loss between 25 and 145°C suggesting that the citrate Form **H** might be a dihydrate (the theoretical weight loss upon dehydration of a citrate monohydrate is 3.17%).

5 **Hygroscopicity**

The hygroscopicity of the citrate salt was assessed. Two stepwise 3% wt. increases at 15%RH and 90%RH were observed. The weight gains are reversible implying hydration/dehydration in the experimental time scale. The citrate salt Form **G** is only slightly hygroscopic.

10

Solubility

The solubility of the forms in water was assessed. For Form **G**, the drug concentration in the supernatant is 5.1 mg/mL and the pH of the resulting aqueous solution is 2.6. The drug concentration in the supernatant of Form **H** suspension is 5.4 mg/mL and the pH of the resulting aqueous solution is 2.5. The suspended solids were recovered and analyzed by XRPD. The XRPD patterns of the recovered solids are identical but different from the initial solids forms **G** and **H**, and Form **I** was identified. (Figure 8)

20 **IV . Besylate Salts (Forms J and K):**

A solution of crude Compound **4-4** (3.26g, 3.00g assay) in a mixture of DMAc (15 mL) and THF (15 mL) is treated with Darco G60 (0.60g) for 3 hours. The mixture is filtered and the filter cake is rinsed with 3/2 DMAc/THF (5 mL). A solution of benzenesulfonic acid (1.58g) in THF (5 mL) is added (1.5 mL is added first and seeded with 30 mg of the besylate salt and then aged for 1 hour). The remaining portion is added slowly over 2 hours. The mixture is aged for 2 hours and filtered. The filter cake is washed with 3/2 DMAc/THF ((5 mL) then acetone (6 mL). The partially dry filter cake is then reslurried in 5/1 acetone/H₂O (12 mL) overnight. More acetone (10 mL) is added and after aging for 5 hours, the mixture is filtered. The filter cake is washed with acetone (10 mL) and air dried to give the besylate salt of Compound **4-4** as a white solid.

X-Ray Powder Diffraction (XRPD)

The XRPD patterns of the besylate salt indicate two distinct crystalline solid forms. (Figures 10 and 11).

5 Thermal Properties

DSC

The DSC of the besylate salt (Form **J**) shows no thermal events before the melting transition at 234°C, at a heating rate of 5°C/min. Form **K** has melting
10 transition at 232°C, at a heating rate of 5°C/min.

TGA

The TGA shows a 0.9% wt. loss between 25 and 220°C, suggesting that the crystalline Form **J** is anhydrous. Form **K** is also anhydrous based on TGA
15 data.

Hygroscopicity

The anhydrous besylate salt (Form **J**) is nonhygroscopic gaining only 0.3% wt. at 75% RH. Form **K** is anhydrous and nonhygroscopic.

20

Solubility

The solubility of the besylate salt (Form **J**) in water is 0.51 mg/mL and the pH of the resulting aqueous layer is 3.6. The XRPD of the solid recovered from the aqueous suspension shows no change in forms. When form **K** is suspended in
25 water, it converts to form **J**.

30

The X-ray powder diffraction patterns for the hydrochloride salt (Forms **C**, **D**, **E** and **F**), hydrochloride ethanolate, tartrate salt, citrate salts (Forms **G**, **H** and **I**) and the besylate salts (Forms **J** and **K**) are illustrated in Figures 1 to 11. The X-ray powder diffraction data for these salts are summarized below in the tables.
below:

Hydrochloride Salt (Form C)

	d-spacing (Å)	2-theta (°)	relatively intensity (%)
5	19.65	4.49	39.6
	9.73	9.08	100.0
	8.00	11.05	42.3
	4.99	17.76	16.8
	4.55	19.50	13.7
	4.16	21.36	12.4
10	3.87	22.99	26.1
	3.22	27.69	51.7
	2.71	33.07	10.5
	2.57	34.94	12.6

HCl monohydrate form D

15	d-spacing (Å)	2-theta (°)	relatively intensity (%)
	9.67	9.14	16.73
	7.95	11.13	69.22
	5.66	15.65	20.77
	4.97	17.84	83.69
	4.53	19.60	100.00
	4.14	21.44	38.96
	3.72	23.92	24.95
	3.64	24.46	19.15
	3.54	25.17	19.62
	3.45	25.80	36.90
	3.43	25.98	16.38
	3.15	28.35	26.90
	3.01	29.65	18.32

Hydrochloride Salt (Form E)

	d-spacing (Å)	2-theta (°)	relatively intensity (%)
5	21.36	4.13	38.3
	10.79	8.19	20.9
	8.87	9.97	16.3
	7.21	12.27	24.5
	5.82	15.21	32.9
10	5.57	15.91	100.0
	5.35	16.56	21.5
	4.45	19.95	27.7
	4.39	20.23	27.7
	3.58	24.88	22.1
	3.35	26.56	27.0

Dehydrated HCl monohydrate D (Form F)

d-spacing (Å)	2-theta (°)	relatively intensity (%)
8.70	10.17	50.39
6.95	12.74	19.15
5.90	15.01	47.34
5.77	15.35	18.44
5.51	16.09	38.61
5.13	17.29	83.47
4.96	17.89	38.57
4.82	18.42	19.15
4.70	18.88	51.44
4.66	19.04	37.06
4.44	20.00	21.82
4.34	20.45	51.22
4.14	21.49	20.19
3.90	22.78	34.95
3.64	24.44	46.45
3.52	25.33	22.76
3.42	26.04	100.00
3.09	28.86	27.51
2.95	30.31	25.59
2.89	31.00	19.56

HCl ethanolate

d-spacing (Å)	2-theta (°)	relatively intensity (%)
14.52	6.09	25.08
8.07	10.96	39.41
7.36	12.03	27.86
5.37	16.52	76.38
5.28	16.79	90.44
4.93	17.99	35.49
4.84	18.31	47.10
4.82	18.41	33.40
4.47	19.87	37.80
4.44	20.01	33.69
4.15	21.42	45.18
4.11	21.63	46.30
3.59	24.82	28.50
3.56	25.04	25.54
3.50	25.44	100.00
3.45	25.81	72.25
3.28	27.16	28.24
2.99	29.92	45.23
2.57	34.89	25.86
2.47	36.43	28.19

Tartrate Salt

d-spacing (Å)	2-theta (°)	relatively intensity (%)
8.66	10.22	100.00
7.94	11.14	53.18
6.59	13.44	32.22
6.20	14.28	51.33
5.29	16.76	46.63
3.89	22.86	41.16
3.56	24.98	57.94
3.43	25.94	52.71
3.11	28.72	33.26
2.99	29.86	22.28

Citrate Salt (Form H)

d-spacing (Å)	2-theta (°)	relatively intensity (%)
43.40	2.04	51.58
21.25	4.16	100.00
5.47	16.21	55.44
5.43	16.31	50.63
5.23	16.94	31.53
5.01	17.72	55.53
4.75	18.66	45.12
4.53	19.61	25.53
4.37	20.34	36.24
4.24	20.97	29.44
4.18	21.28	49.62
4.14	21.46	40.18
3.88	22.94	29.92
3.71	23.98	28.75
3.29	27.10	39.01
3.20	27.85	30.46
3.15	28.30	32.29

Citrate (Form I)

d-spacing (Å)	2-theta (°)	relatively intensity (%)
19.60	4.51	40.86
6.30	14.07	24.73
5.87	15.09	20.53
5.70	15.55	19.70
5.60	15.82	45.81
5.21	17.02	23.60
5.01	17.70	58.55
4.77	18.60	54.61
4.29	20.70	54.36
3.96	22.42	100.00
3.75	23.71	19.02
3.63	24.52	40.77
3.51	25.40	20.40
3.41	26.13	31.20
3.20	27.91	41.59
3.14	28.46	18.11
3.12	28.58	16.39

Besylate Salt (Form J)

d-spacing (Å)	2-theta (°)	relatively intensity (%)
9.27	9.54	27.72
9.02	9.80	16.20
6.86	12.90	43.72
5.54	15.99	17.68
4.79	18.54	27.53
4.27	20.82	17.67
4.20	21.16	100.00
3.63	24.51	22.50

Besylate Salt (Form K)

5

d-spacing (Å)	2-theta (°)	relatively intensity (%)
10.21	8.66	36.94
5.58	15.88	57.26
5.45	16.27	22.81
4.91	18.05	20.21
4.81	18.43	100.00
4.29	20.73	39.95
3.88	22.94	30.98
3.86	23.06	18.83
3.76	23.64	24.69
3.72	23.92	29.45
3.66	24.34	16.19
3.63	24.51	32.89